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Metastasis of cancer to distant organs is the major cause of its lethality. With 
recent studies highlighting the role of the premetastatic niche in supporting 
metastatic progression, we focused our efforts on understanding the interplay 
between reprogrammed microenvironments in distal organs and tumor cells, to 
determine novel mechanisms that contribute to metastasis progression and 
identify potential targets for metastasis suppression. Our investigations 
unraveled a critical role of the anti-tumorigenic factor thrombospondin-1 (Tsp-
1) in the reprogrammed lung microenvironment. 
 
Premetastatic niches generated in the lungs by metastasis-incompetent 
primary tumors showed elevated Tsp-1 expression. Interestingly, Gr1+ myeloid 
cells in the lungs were the major producers of Tsp-1, and they responded to 
the tumor-derived factor prosaposin (psap), abundantly secreted by 
metastasis-incompetent tumors compared to their metastatic counterparts. 
Further analysis led to the identification of the pentapeptide sequence, 
DWLPK, within psap that retains Tsp-1-inducing activity. Using DWLPK, 
recapitulated Tsp-1 induction in Gr1+ cells in the lungs and suppressed 
metastasis of Lewis lung carcinoma cells. These results suggest that DWLPK 
can potentially serve as a therapeutic agent for metastasis suppression. 
 
Studying metastasis in the setting of pre-existing lung inflammation, we 
observed loss of Tsp-1 in the lung microenvironment.  Intranasal 
administration of bacterial lipopolysaccharide (LPS) induced lung 
inflammation, characterized by recruitment of Ly6G+ neutrophils, and it 
enhanced metastatic burden. Inflammation was accompanied by an increase 
in neutrophil elastase (NE) and cathepsin G (CG) protease activity, and loss of 
Tsp-1 protein in lungs. Our studies confirmed that NE and CG degrade Tsp-1 
in lungs in response to LPS-induced inflammation, thus promoting metastasis. 
Interestingly, blocking the neutrophil proteases pharmacologically using the 
dual protease inhibitor Sivelestat suppressed metastasis, indicating that the 
proteases are clinically viable anti-metastatic therapeutic targets. 
 
Our studies demonstrate the novel finding that metastasis-incompetent tumors 
render the distal site metastasis-suppressive, by systemically inducing Tsp-1 
expression in recruited myeloid cells. On the other hand, we have described a 
novel mechanism, where inflammation leads to Tsp-1 degradation via 
neutrophil proteases, generating a metastasis-promoting microenvironment. 
Our findings highlight the context-dependent plasticity of Ly6G+ cells at distal 
sites, functioning as the main source of anti-tumorigenic Tsp-1 and the 
proteases that degrade it. 
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CHAPTER ONE 
INTRODUCTION 
 
Metastasis is the major cause of cancer-related deaths. This has fueled 
studies to understand mechanisms of metastasis for the purpose of devising 
novel therapeutic approaches. Earlier studies examining mechanisms of 
metastasis focused solely on cancer cell-intrinsic properties that drive steps in 
the metastatic cascade, such as tumor cell invasion, migration, and 
extravasation, as well as homing to specific distant organs (Nguyen and 
Massagué, 2007; Yang et al., 2004a). However, recent studies have shed light 
on the critical role of immune/inflammatory cells that make up the 
microenvironment of the metastatic organ in supporting the steps of the 
metastatic cascade, including metastatic seeding and outgrowth (Joyce and 
Pollard, 2009). By understanding how changes in the premetastatic 
microenvironment impact tumor cell metastatic ability, our aim is to target the 
more genetically stable cell components of the microenvironment to hinder 
metastatic progression. 
 
My doctoral thesis has focused on uncovering the reprogrammed 
microenvironments in distant metastatic organs generated by metastasis-
incompetent and metastasis-competent tumors. Moreover, I have evaluated 
the effect of heightened inflammatory conditions in the distant organs on 
metastasis progression. The hope is that understanding the mechanisms 
operating in the metastatic organs can pave the way to new therapeutic 
approaches that target the metastasis-promoting microenvironment, 
irrespective of tumor-intrinsic properties or disparities among tumors. 
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1-1. The premetastatic niche 
In 1889, Stephen Paget proposed the “seed and soil” hypothesis, where he 
posited that cancer cells, “the seed”, had an affinity for and colonized organs 
that were conducive to their growth, or had the proper “soil”, and that 
metastasis was not a random event (Fidler, 2003). Strikingly in agreement with 
the “seed and soil” hypothesis, emerging evidence from recent studies shows 
that a conducive microenvironment is required for disseminated tumor cells to 
engraft distant sites. Furthermore, metastatic tumors themselves systemically 
establish bone marrow (BM)-derived “premetastatic niches” in distant organs 
that serve as permissive hubs for supporting future metastasis (Psaila and 
Lyden, 2009). These premetastatic niches are characterized by the induction 
of organ-specific chemoattractants, growth factors and extracellular matrix 
(ECM)-related proteins, as well as the recruitment of bone marrow-derived 
cells, like vascular endothelial growth factor receptor (VEGFR)1+ 
hematopoietic progenitor cells and CD11b+ myeloid cells (Gao et al., 2012; 
Hiratsuka et al., 2006; Kaplan et al., 2005; Kim et al., 2009; Qian et al., 2011) 
(Figure 1.1). 
The “premetastatic niche” model implies that it is not only a tumor cell’s 
intrinsic properties that dictate its metastatic fate but that the generation of a 
conducive environment at the distant site is necessary to allow the outgrowth 
of disseminated tumor cells into secondary metastases (Kaplan et al., 2005). 
 
The first description of the premetastatic niche involved the clustering of 
hematopoietic progenitor cells in the lungs, preceding and necessary for tumor  
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Figure 1.1. The premetastatic niche. Metastatic primary tumors, by systemically secreting VEGF, TNFα, and TGFβ, induce the recruitment of bone marrow-derived cells (BMDCs), such as endothelial progenitor cells (EPCs), platelets, mesenchymal stem cells (MSCs), and hematopoietic progenitor cells (HPCs) to the lung. These BMDCs form the premetastatic niche, together with induced chemoattractants, proteases, and ECM components. For instance, metastatic primary tumors systemically induce the expression of fibronectin in lung fibroblasts, leading to the recruitment of VEGFR1+ HPCs via their fibronectin receptor, VLA-4.  VEGFR1+ cells in turn secrete MMP9 in response to tumor-derived VEGF, modifying the lung ECM. VEGF, TNFα, and TGFβ secreted by primary tumors induce the expression of S100A8 and S100A9 in the lung microenvironment, recruiting myeloid cells. S100A8 and S100A9 activate the expression of SAA3, leading to TLR4 signaling and NF-κB activation, promoting an inflammatory state. Hypoxic primary tumors release lysyl oxidase (LOX), which crosslinks collagen in the lungs, increasing the retention of myeloid cells and tumor cells.  Myeloid cells recruited to the lungs secrete the factor versican, which induces MET in disseminated tumor cells, allowing metastatic outgrowth. And VEGFR2+ EPCs are recruited to induce the angiogenic switch, allowing micrometastases to develop to macrometastases in the lungs. (Modified from Psaila and Lyden, 
2009). 
 
 
 
 
Figure 1.1
4 
 
metastasis. In this model, tumor cells systemically upregulated the expression 
of fibronectin in lung resident fibroblasts, leading to the recruitment of bone 
marrow-derived VEGFR1+ hematopoietic progenitor cells via their fibronectin 
receptor, VLA-4 (Kaplan et al., 2005). A more recent study found that CXCR4-
mediated recruitment of Gr1+ myeloid cells into the lungs enhanced lung 
metastasis, independent of vascular endothelial growth factor 
(VEGF)/VEGFR1-mediated recruitment of tumor–associated macrophages 
(TAMs) (Hiratsuka et al., 2011). 
 
Primary tumors, by secreting VEGFA, transforming growth factor β (TGFβ), 
and tumor necrosis factor α (TNFα), can systemically induce the expression of 
chemoattractants, like S100A8 and S100A9, in the premetastatic lungs, 
leading to recruitment of CD11b+ myeloid cells, which in turn express 
migration-stimulating factors, such as TNFα and TGFβ, enhancing tumor cell 
metastasis (Hiratsuka et al., 2006). In addition, S100A8 and S100A9 induce 
the expression of serum amyloid A3 (SAA3) in premetastatic lungs, resulting in 
the activation of NF-κB signaling via toll-like receptor 4 (TLR4) on myeloid 
cells, creating an inflammatory state and further accelerating lung metastasis 
(Hiratsuka et al., 2008). Furthermore, primary tumor-derived CCL2 can 
stimulate CCR2 on lung endothelial cells, inducing the secretion of S100A8 
and SAA3, which signal via TLR4 to increase vascular permeability, creating 
hyperpermeable foci in the lungs that attract leukocytes and tumor cells 
(Hiratsuka et al., 2013). 
VEGF secreted by primary tumors induces the expression of matrix 
metalloprotease 9 (MMP9) in the premetastatic lung in cells that express 
VEGFR1, including CD11b+ myeloid cells and endothelial cells (Hiratsuka et 
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al., 2002). MMP9 in the premetastatic niche can facilitate tumor cell 
extravasation, as well as release growth factors from the ECM, like VEGF to 
promote angiogenesis (Bergers et al., 2000), and chemokines like soluble KIT 
ligand, which further recruits bone marrow-derived cells expressing the KIT 
receptor (Heissig et al., 2002). 
Bladder cancer-derived proteoglycan versican enhances tumor cell metastasis 
to the lungs via a mechanism that upregulates CCL2 chemokine levels in the 
lungs and increases macrophage infiltration (Said et al., 2012). Consistent with 
that study, the recruitment of CCR2-expressing monocytes and macrophages 
to the lungs in response to metastatic tumor cell-derived and host tissue-
derived CCL2 enhances breast tumor metastasis to the lungs, in part due to 
the expression of VEGF by recruited monocytes, promoting tumor cell 
extravasation (Qian et al., 2011). Furthermore, versican expressed by LLC 
tumor cells activates TLR2:TLR6 complexes on myeloid cells, inducing TNFα 
secretion by myeloid cells and enhancing tumor cell metastatic growth (Kim et 
al., 2009). On the other hand, versican expressed by CD11b+ Gr1+ Ly6Chigh 
myeloid progenitor cells in the premetastatic lung contributes to the 
mesenchymal-to-epithelial transition (MET) of disseminated metastatic tumor 
cells, consequently increasing cell proliferation and accelerating lung 
metastasis of breast tumors (Gao et al., 2012). 
 
It has also been shown that hypoxic primary tumors secrete lysyl oxidase 
(LOX), which acts systemically to crosslink collagen in lungs. This allows the 
retention of CD11b+ myeloid cells in the lungs, which in turn secrete MMP2, 
releasing collagen fragments that are chemoattractive to myeloid cells and 
tumor cells, hence promoting metastatic progression (Erler et al., 2009). 
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Together these studies have established the ability of metastasis-competent 
primary tumors to generate a premetastatic niche. This thesis will first 
characterize the premetastatic niches generated by metastasis-incompetent 
tumors to determine mechanisms of metastasis suppression. Next, it will 
address the role of extrinsic inflammation in promoting metastasis, based on 
the hypothesis that the inflammatory microenvironment created would 
resemble the tumor-derived inflammatory component of the premetastatic 
niche. 
 
1-2. Thrombospondin-1 (Tsp-1) 
In the year 1990, thrombospondin-1 (Tsp-1) was identified as the first 
endogenous inhibitor of angiogenesis, inhibiting endothelial cell migration and 
neovascularization in the rat cornea (Good et al., 1990). The identification of 
endogenous angiogenesis inhibitors paved the way to the understanding that 
regulation of angiogenesis depends on a balance between promoter and 
inhibitor activities. In the context of tumors, angiogenesis is required for tumor 
progression, so Tsp-1 is an important regulator of tumor progression. 
Tsp-1 expression is regulated by a tumor suppressor (Good et al., 1990), later 
identified as p53 (Dameron et al., 1994; Kang et al., 2009). 
 
Structure of Tsp-1 
Tsp-1 is one of five thrombospondins in mammals (Tsp-1 - Tsp-5). Tsp-1 
protein consists of three polypeptide chains of equivalent molecular weight. 
The trimer has a molecular weight of around 450 kDa, while each monomeric 
chain has a molecular weight of 150 kDa (Figure 1.2). The three chains are 
crosslinked proximal to the N-terminal domain via inter-chain disulfide bonds.  
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Figure 1.2. The structure of Tsp-1. Tsp-1 exists as homotrimer. Each 
monomer (pictured above) consists of a globular NH2-terminal domain, known 
as the heparin-binding domain, interchain disulfides, which allow Tsp-1 
monomers to trimerize, a procollagen homology domain (PC), Type I, II, and III 
repeats, and a globular carboxyl terminal. The RGD sequence within the last 
Type III repeat is the binding site for integrins. (Modified from Lopez-Dee et al., 
2011).  
Figure 1.2
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Structurally, a Tsp-1 monomer consists of an NH2-terminal globular domain, 
known as the heparin-binding domain, inter-chain disulfides, a procollagen 
domain, three type I repeats (TSR), three EGF-like repeats, seven Ca2+-
binding repeats, the last of which contains an RGD sequence that allows it to 
interact with αvβ3 integrin, and a COOH terminal domain (Bornstein, 1992; 
Lopez-Dee et al., 2011). 
 
Tsp-1 in wound healing 
Under conditions of wound healing, the synthesis of Tsp-1 occurs in 
megakaryocytes. Platelet Tsp-1 is stored in α-granules and released upon the 
binding of thrombin to platelets. A thrombin-thrombospondin complex forms on 
the surface of platelets, and this occurs through a thiol-disulfide bond between 
a free thiol group on Tsp-1 and a disulfide on thrombin (Lawler, 1986). Tsp-1 
binds platelets through its carboxyl-terminal and mediates platelet aggregation 
(Rabhi-Sabile et al., 1996). Tsp-1 is found in clots, bound to fibrinogen via its 
TSR domain (Lawler, 1986; Lee et al., 2006b; Panetti et al., 1999).Tsp-1 also 
binds von Willebrand factor and coagulation factors IXa and Xa (Lawler, 
1986). 
 
Tsp-1 binding partners 
Tsp-1 is synthesized and secreted by diverse cell types, including endothelial 
cells, fibroblast, epithelial cells (Lawler, 1986), as well as monocytes and 
macrophages (Jaffe et al., 1985). However, activated macrophages reduce 
their secretion of Tsp-1 (Jaffe et al., 1985). 
Tsp-1 binds numerous ECM proteins, including heparin, fibronectin, fibrinogen, 
type V collagen, and plasminogen (Lawler, 1986). 
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The different functions of Tsp-1 depend on its presence in the ECM 
environment. However, Tsp-1 undergoes different fates, including cellular 
uptake, proteolysis, or ECM retention. For instance, interaction of the N-
terminal domain of Tsp-1 with heparan sulfate proteoglycans or low-density 
lipoprotein receptor-related protein (LRP) leads to its endocytic internalization 
and intracellular proteolysis (Gupta et al., 1999), while in the ECM, Tsp-1 can 
undergo processing by different enzymes (Bonnefoy and Legrand, 2000; Hogg 
et al., 1994; Lee et al., 2006b; Rabhi-Sabile et al., 1996). Finally, Tsp-1 
retention in the ECM is mediated by the C-terminal domain of Tsp-1 trimers, 
and depends on the C-terminal RGD motif as well as a site in the L-lectin 
domain, but is independent of CD47, β1-integrins, αvβ3 integrin, and 
fibronectin (Adams et al., 2008). 
 
Tsp-1 cleavage fragments and their functions 
In the ECM, Tsp-1 is exposed to proteases that mediate its cleavage. 
Exposure of Tsp to α-thrombin in the presence of Ca2+ leads to selective 
cleavage of a 25 kDa amino-terminal heparin-binding fragment and an anti-
angiogenic 140 kDa carboxyl-terminal fragment (Lawler, 1986; Taraboletti et 
al., 1997). Cleavage of the Tsp-1 amino-terminal heparin-binding domain is 
also mediated by thermolysin, plasmin, trypsin, chymotrypsin, and cathepsin G 
(Lawler, 1986; Rabhi-Sabile et al., 1996). 
The anti-angiogenic function of Tsp-1 has been attributed to three peptide 
sequences in the 140 kDa carboxyl-terminal fragment, one being in the 
procollagen domain and the other two in the type I repeats (TSR domain) 
(Tolsma et al., 1993; Vogel et al., 1993). More recently, it was shown that 
ADAMTS1, a secreted metalloprotease, cleaves Tsp-1 within the procollagen 
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domain, in the proximity of the inter-chain disulfide bonds, releasing a trimeric 
N-terminal domain, composed of individual 36 kDa fragments, and soluble 110 
kDa C-terminal monomers, which suppress VEGF- and FGF2-activated 
endothelial cell proliferation (Lee et al., 2006b). 
 
Interestingly, the 25 kDa amino-terminal heparin-binding fragment of Tsp-1, 
released through thrombin cleavage, induces angiogenesis in the rabbit 
cornea by promoting endothelial cell invasiveness. The 25 kDa fragment 
induces the synthesis and activation of MMP2, and downregulates the 
expression of the MMP2 inhibitor TIMP2 in endothelial cells (Taraboletti et al., 
2000). This account demonstrates that Tsp-1 can be a source of smaller 
fragments that mediate angiogenesis, hence opposing the antiangiogenic 
function of full-length Tsp-1, or the 140 kDa fragment of Tsp-1. 
 
Non-receptor-mediated Tsp-1 anti-angiogenic functions 
bFGF binds to full-length Tsp-1 and the C-terminal 140 kDa antiangiogenic 
fragment generated by thrombin cleavage. Tsp-1 thus inhibits binding of bFGF 
to endothelial cells, and concurrently inhibits endothelial cell proliferation in 
response to bFGF (Taraboletti et al., 1997). 
Tsp-1 binds inactive MMP2 and MMP9 zymogens, inhibiting their activation 
(Bein and Simons, 2000), consequently inhibiting MMP9-mediated release of 
VEGF from the ECM (Rodriguez-Manzaneque et al., 2001). Tsp-1 also directly 
binds VEGF and leads to its clearance from the ECM via intake of the Tsp1-
bound VEGF by LRP1 (Gupta et al., 1999; Lawler and Lawler, 2012). 
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Receptor-mediated Tsp-1 anti-angiogenic functions 
Tsp-1 can induce apoptosis of endothelial cells. Binding of Tsp-1 to the CD36 
receptor on endothelial cells induces their apoptosis via the activation of 
mitochondrial-dependent and independent apoptotic cascades, downstream of 
the Src family kinase Fyn (Jiménez et al., 2000; Lawler and Lawler, 2012; Ren 
et al., 2009).  
Tsp-1 can inhibit endothelial cell proliferation in response to VEGF. Binding of 
Tsp-1 to endothelial CD36 promotes the association of CD36 with β1 integrins, 
inhibiting phosphorylation of VEGFR2 in response to VEGF, hence blocking 
the downstream Akt survival and proliferation signals (Lawler and Lawler, 
2012; Primo et al., 2005). Furthermore, in capillary endothelial cells, the 
binding of Tsp-1 to very-low-density lipoprotein receptor (VLDLR) inhibits cell 
cycle progression via Akt and MAPK pathways (Oganesian et al., 2008), 
whereas in larger vessels, Tsp-1 inhibits cell cycle progression by binding to 
CD36, activating p53 and p21 (Lawler and Lawler, 2012; Yamauchi et al., 
2007). 
Although binding of Tsp-1 to CD36 or CD47 blocks nitric oxide (NO) 
production in endothelial cells, only CD47 is required, and this leads to 
inhibition of endothelial cell migration, proliferation, and survival, as well as 
vascular permeability (Isenberg et al., 2007). 
 
Receptor-mediated Tsp-1 anti-tumor functions 
Tsp-1 can also act directly on tumors, blocking their proliferation or inducing 
their apoptosis. Tsp-1 type I repeats inhibit melanoma proliferation via a 
CD36-independent mechanism, which seems to require a protein tyrosine 
phosphatase, since the effect is blocked by the tyrosine phosphatase inhibitor 
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vanadate (Guo et al., 1998). Furthermore, Tsp-1 inhibits cell proliferation of 
B16-F10 melanoma cells in a TGFβ-dependent manner (Miao et al., 2001), 
which requires the TSR2 domain of Tsp-1 containing the RFK sequence that 
activates latent TGFβ (Miao et al., 2001; Schultz-Cherry et al., 1994, 1995). In 
vivo, Tsp-1 was able to increase melanoma tumor apoptosis, through TGFβ 
activation (Miao et al., 2001).  
 
1-3. Thesis Aims 
The ability of metastasis-competent primary tumors to generate metastasis-
promoting premetastatic niches in distal organs is well described. However, 
similar information on metastasis-incompetent tumors is lacking. We 
considered three potential scenarios that could explain the inability of 
metastatic-incompetent tumors to metastasize. 1- Metastasis-incompetent 
tumors generate a premetastatic niche, but tumor-intrinsic properties prevent 
metastasis. 2- Metastasis-incompetent tumors do not generate a premetastatic 
niche. 3- Metastasis-incompetent tumors generate a niche in the distant organ 
that is molecularly different than the one generated by metastasis-competent 
tumors. Chapter two of this thesis will address this question and evaluate the 
distal microenvironment established by metastasis-incompetent tumors, in the 
goal of finding tumor-derived factors that systemically alter the distal site and 
block metastatic outgrowth, and making use of them therapeutically. 
 
Another key question that will be addressed in chapter three of this thesis is 
whether external inflammation has the potential to promote metastasis, as the 
inflammatory microenvironment resembles the tumor-derived inflammatory 
component of the premetastatic niche. The aim is to recapitulate the 
13 
 
mechanism(s) that enhance metastatic outgrowth, revealing therapeutically 
actionable targets for metastasis suppression. 
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CHAPTER TWO1
METASTASIS-INCOMPETENT TUMORS SYSTEMICALLY INDUCE TSP-1 
IN LUNG GR1+ MYELOID CELLS. 
 
2-1. INTRODUCTION 
Emerging data demonstrate that metastatic primary tumors systemically alter 
the distal site of metastasis, creating a premetastatic niche that is required for 
metastatic tumor colonization and outgrowth.  However, the impact of 
metastasis-incompetent tumors on the premetastatic niche has not been 
previously described. This chapter will interrogate the ability of metastasis-
incompetent tumors to systemically influence distant metastatic organs, with a 
focus on the tumor-derived secreted factor prosaposin, which systemically 
alters the lung microenvironment by modulating Tsp-1 production, rendering it 
metastasis-suppressive. 
Preceding our studies, prosaposin had been described as an anti-metastatic 
factor highly secreted by cancer cells with a low metastatic potential, and 
capable of inducing Tsp-1 expression in stromal cells (Kang et al., 2009). We 
demonstrated that tumor-derived psap induced Tsp-1 expression in myeloid 
cells recruited to the lungs, leading to metastasis suppression. In addition, the 
psap-derived pentapeptide DWLPK likewise induced Tsp-1 expression in lung 
myeloid cells and inhibited metastasis, indicating a potential for therapeutic 
intervention. 
                                                            
1 Results presented in this chapter have been published in: Catena R, Bhattacharya N, El 
Rayes T, Wang S, Choi H, Gao D, Ryu S, Joshi N, Bielenberg D, Lee SB, Haukaas SA, 
Gravdal K, Halvorsen OJ, Akslen LA, Watnick RS, Mittal V. Bone marrow-derived Gr1+ cells 
can generate a metastasis-resistant microenvironment via induced secretion of 
thrombospondin-1. Cancer Discov. 2013 May;3(5):578-89. 
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2-1.1. Prosaposin structure and processing 
Prosaposin is a 75 kDa polypeptide precursor of four saposin proteins, which 
are heat-stable activators of glycosphingolipid hydrolases that reside in the 
lysosome, and hence play a role in glycosphingolipid metabolism. Proteolytic 
processing of prosaposin in the lysosome releases the four saposins A-D, of 
lower molecular weight (9-11 kDa) (Hiesberger et al., 1998; Sandhoff and 
Kolter, 1997).  
Prosaposin is synthesized as a 65 kDa polypeptide in the endoplasmic 
reticulum (ER), and then further converted into the 73 kDa form in the Golgi 
apparatus after glycosylation. Furthermore, both the 65 and the 73 kDa 
prosaposin forms contain phosphate groups on N-linked oligosaccharide chain 
(carbohydrate-linked phosphate) on saposin C and saposin D domains while 
only the 73 kDa prosaposin has sulfate residues on the saposin A and saposin 
C domain, suggesting that phosphorylation occurs in the ER and sulfation in 
the Golgi (Vielhaber et al., 1996). 
A major fraction of synthesized prosaposin is secreted outside the cell, 
whereas part of it is directly intracellularly shuttled to the lysosome, for 
processing into saposins. This occurs through the binding of the mannose-6-
phosphate (M-6-P) residues on prosaposin to the mannose-6-phosphate 
receptor (MPR) (Vielhaber et al., 1996). On the other hand, most of the 
endocytic re-uptake of secreted prosaposin occurs independently of MPR, via 
the mannose receptor on macrophages and LRP1 expressed ubiquitously on 
most cells (Hiesberger et al., 1998). 
Once endocytosed, prosaposin is delivered to the lysosome, where it 
undergoes processing into the saposins by the aspartyl protease, cathepsin D 
(Hiraiwa et al., 1997). Interestingly, the binding of prosaposin to the 
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glycosphingolipid ganglioside GM1 protects it from processing by cathepsin D 
(Hiraiwa et al., 1997). 
 
2-1.2. Known functions of Psap 
In addition to being a lysosomal precursor, prosaposin has been described to 
have additional functions, especially since it exists as a secreted protein in 
human milk, cerebrospinal fluid, and seminal plasma (Hiraiwa et al., 1993), 
and its unprocessed form is highly abundant in the brain (O’Brien et al., 1988). 
 
Prosaposin is important for the development of male reproductive organs 
(Morales and Badran, 2003), is secreted by Sertoli cells in the testes, and is 
involved in spermatogenesis (McKinnell and Sharpe, 1997) and fertilization 
(Hammerstedt et al., 2001). 
In muscle tissue, prosaposin plays a role in the differentiation of myoblasts to 
myotubes (Rende et al., 2001). 
Prosaposin has neurotrophic functions, and its active region is located in the 
saposin C domain. It stimulates neurite outgrowth of a mouse neuroblastoma 
cell line and choline acetyltranferase (ChAT) activity in a human 
neuroblastoma cell line (O’Brien et al., 1994). Prosaposin also exerts a 
neuroprotective and glioprotective role (Campana et al., 1999; Tsuboi et al., 
1998) via the activation of ERK signaling downstream of the G-protein-coupled 
receptors GPR37 and GPR37L1 (Meyer et al., 2013). 
 
2-1.3. Psap functions in cancer 
In the context of tumorigenesis, prosaposin was found to be secreted by the 
human breast cancer cell lines MDA-MB-231, MDA-MB-435, and MCF7, and 
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its secretion was upregulated in response to 17β-estradiol (Campana et al., 
1999). Higher expression levels of Psap protein and mRNA were observed in 
malignant androgen-independent (AI) prostate cancer cells than in androgen-
sensitive (AS) cells or normal prostate epithelial cells, and this could be 
attributed in some cases to genomic amplification of the Psap gene 
(Koochekpour et al., 2005). Moreover, in prostate cancer, Psap levels in 
serum were found to be downregulated in patients with localized primary 
tumors, but upregulated in patients with castrate-resistant metastatic prostate 
cancer (Koochekpour et al., 2012). Psap can induce the expression of 
androgen receptor (AR), its phosphorylation, and nuclear localization in AR-
positive LNCaP prostate cancer cells (Koochekpour et al., 2007a), while on 
the other hand being an androgen-regulated gene (ARG), where AR binds to a 
hormone-responsive element in the proximal region of the Psap promoter and 
activates Psap expression (Koochekpour et al., 2007b).  
The same is true in AR-expressing prostate stromal cells, where Psap 
functions as an androgen-agonist and an androgen-regulated gene, with the 
interesting addition that conditioned medium from prostate stromal cells can 
induce Psap promoter activity in AI and AS prostate cancer cells, indicating 
paracrine signaling (Koochekpour et al., 2008). 
 
Of specific interest for the purpose of our project is the observation that 
prosaposin secretion is elevated in non-metastatic breast and prostate cancer 
cell lines compared to their metastatic counterparts, and that Psap acts as an 
inhibitor of metastasis via its Tsp-1 induction activity on stromal fibroblasts 
(Kang et al., 2009). Furthermore, Psap mRNA expression was lower in human 
primary tumors that gave rise to metastases than in localized non-metastatic 
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primary tumors (Kang et al., 2009). These studies suggest that Psap is 
secreted by metastasis-incompetent tumors and has the potential to 
systemically alter the microenvironment at the distal site. 
 
2-1.4. LRP1 receptor 
As mentioned above, LRP1 has been reported as a receptor for psap, 
mediating its endocytosis. The LRP1 receptor was identified in the liver as a 
receptor that bound apolipoprotein E (apoE)-containing lipoprotein remnants 
and removed them from circulation (Beisiegel et al., 1989). Interestingly, apoE 
is secreted by cells that themselves express LRP1 or are in close proximity to 
cells that express it, as in the case of hepatocytes, which express LRP1 and 
secrete apoE, and this is thought to drive the synergistic function in the hepatic 
uptake of lipoproteins (Krieger and Herz, 1994). LRP1 was soon after found to 
be the receptor responsible for clearing from the circulation the proteinase 
inhibitor α2-macroglobulin bound to proteases (Kristensen et al., 1990; 
Strickland et al., 1990). LRP1 in the liver is also highly expressed on Kupffer 
cells, the liver resident macrophages, where it internalizes protease inhibitors 
complexed with proteases, chylomicron remnants, and activated coagulation 
factors, leading to their intracellular degradation (Lillis et al., 2008). 
Since then, LRP1 has been reported to have high affinity for numerous ligands 
and to internalize them (Lillis et al., 2008). For instance, LRP1 has been 
shown to bind and clear the plasminogen activators, tissue-type plasminogen 
activator (tPA) and urokinase-type plasminogen activator (uPA), bound to their 
inhibitor, plasminogen activator inhibitor-1 (PAI-1) (Nykjaer et al., 1992; Orth et 
al., 1992). Plasminogen activators are serine proteases that convert 
plasminogen into active plasmin, a broad spectrum protease that plays a role 
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in matrix restructuring, wound healing, and invasion. Hence, LRP1 regulates 
pericellular proteases and can influence cell invasion. On one hand, LRP1 
expression was associated with a less invasive phenotype of breast and 
prostate cancer cell lines, possibly due to the endocytosis of the proteases 
(Kancha et al., 1994). On the other hand, LRP1 cell surface expression was 
positively correlated with invasiveness of several breast cancer cell lines (Li et 
al., 1997, 1998), and LRP1 was expressed on the leading edge of invading 
cells (Chazaud et al., 2002). 
 
Based on all these observations, LRP1 was originally thought to function 
simply as an endocytic receptor, but data now suggests that it also plays a role 
in intracellular signaling. 
 
LRP1 is expressed on a number of cell types, including hepatocytes and 
Kupffer cells in the liver, monocytes in lung and lymphoid tissue, and neuronal 
cells and astrocytes in the brain (Moestrup et al., 1992), where it can bind 
amyloid precursor protein (APP) (May et al., 2002). LRP1 deletion in mice 
causes embryonic lethality, demonstrating its essential role during 
development, with one study suggesting it plays a role in embryo implantation 
(Herz et al., 1992). 
 
LRP1 transcription and protein expression are downregulated in macrophages 
by lipopolysaccharide (LPS) and interferon-γ (IFN- γ) (LaMarre et al., 1993), 
and upregulated by colony-stimulating factor-1 (CSF1) (Hussaini et al., 1990). 
Furthermore, LRP1 is redistributed from intracellular compartments to the cell 
membrane in response to insulin (Descamps et al., 1993). 
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LRP1 is synthesized in the ER as a single polypeptide precursor and is 
cleaved by the processing protease furin in the Golgi into the 85 kDa single-
pass transmembrane C-terminal subunit and an N-terminal 515 kDa large 
extracellular domain that remains non-covalently associated with the 85 kDa 
subunit (Krieger and Herz, 1994; Willnow et al., 1996a). The 515 kDa 
extracellular subunit contains the ligand-binding domains of LRP1, whereas 
the 85 kDa subunit consists of the transmembrane domain and the 
cytoplasmic domain of LRP1. In the ER, a resident chaperone protein called 
receptor associated protein (RAP) prevents newly translated LRP1 from 
binding to ligands and aggregating, hence allowing proper delivery of LRP1 to 
the cell membrane (Herz et al., 1991; Williams et al., 1992; Willnow et al., 
1996b). The lower pH encountered by the RAP/LRP1 complex in the Golgi 
leads to the release of LRP1 from RAP (Bu et al., 1995; Lee et al., 2006a). 
 
Being a member of the low density lipoprotein (LDL) receptor family, the 
extracellular domain of LRP1 contains cysteine-rich complement-type repeats 
(CR), arranged into four clusters, termed clusters I-IV. Most binding to LRP1 
occurs at clusters II and IV (Neels et al., 1999). Furthermore, the extracellular 
domain of LRP1 is made up of two cysteine-rich EGF-like repeats, a β-
propeller YWTD repeat, and a third EGF-like repeat. The β-propeller domain 
functions in the uncoupling of LDL receptor family members from ligands 
under the low pH conditions of the endosome (Mikhailenko et al., 1999). 
The cytoplasmic domain of LRP1 is 100 amino acids long and contains two 
NPxY motifs that are tyrosine phosphorylated by PDGFR-β, v-scr, and 
connective tissue growth factor (Barnes et al., 2003; Boucher et al., 2002; 
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Yang et al., 2004b). In addition, LRP1 cytoplasmic domain can bind several 
adaptor molecules (Gotthardt et al., 2000). 
 
LRP1 and PDGFR-β are closely located in caveolae (Boucher et al., 2002). 
PDGF-BB binds PDGFR and can bind directly to the extracellular domain of 
LRP1 (Loukinova et al., 2002). This leads to the tyrosine phosphorylation of 
the second NPxY motif of the LRP1 cytoplasmic domain by scr-family kinases, 
via a mechanism dependent on PDGFR-β, creating a docking site for Shc 
adaptor protein on LRP1, allowing LRP1 to function in intracellular signaling 
events (Boucher et al., 2002; Loukinova et al., 2002). Furthermore, another 
possible signaling mechanism of LRP1 involves the cleavage and release of 
its intracellular domain from the cell membrane by a gamma secretase-like 
activity, where it has the potential to translocate to the nucleus and participate 
in transcriptional regulation (May et al., 2002). LRP1 intracellular domain 
(LRPICD) has been described to translocate to the nucleus and negatively 
regulate amyloid precursor protein (APP)- Fe65 scaffold protein transcriptional 
activity (Kinoshita et al., 2003). 
 
LRP1 is involved in cell migration. The binding of Tsp-1 to a calreticulin-LRP1 
co-complex, where Tsp-1 binds calreticulin, which in turn binds LRP1, leads to 
the phosphorylation of scr and focal adhesion kinase (FAK), activating ERK 
and PI3K, leading to downstream RhoA inactivation, focal adhesion 
disassembly, and stimulation of cell migration (Orr et al., 2002, 2003a, 2003b, 
2004). Interestingly, direct binding of Tsp-1 to LRP1 leads to its internalization 
and degradation (Mikhailenko et al., 1997). 
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This chapter will explore the ability of metastasis-incompetent tumors to 
generate a premetastatic niche. We determined that metastasis-incompetent 
tumors generate a metastasis-suppressive lung microenvironment that is 
characterized by the induction of Tsp-1 in recruited Gr1+ myeloid cells. We 
further evaluated the therapeutic benefits of exogenously inducing Tsp-1 in the 
lung microenvironment on metastatic outgrowth. To this end, we used a 
peptide derived from the tumor-secreted protein prosaposin, and showed that 
we can suppress metastatic outgrowth. Moreover, mechanistic studies were 
conducted that implicate LRP1 as the receptor that mediates signaling leading 
to Tsp-1 induction in response to prosaposin. 
 
2-2. RESULTS 
2-2.1. Poorly metastatic tumors recruit BM-derived cells to the lungs. 
Studies have shown that metastatic tumors generate a premetastatic niche 
characterized by the recruitment of BM-derived cells to the future site of 
metastasis. However, this phenomenon has not been explored for metastasis-
incompetent tumors, and it remains unknown whether these tumors fail to form 
premetastatic niches, or generate metastasis-refractory niches.  
To determine the nature of the premetastatic niche generated by tumors with 
low metastatic potential, we used human prostate and breast cancer cell lines 
that include the weakly metastatic parental cells, PC3 or MDA-MB-231, and 
their highly metastatic variants, PC3M-LN4 (LN4) and MDA-MB-LM2 (LM2), 
respectively, both of which metastasize to lungs. Furthermore, to recapitulate 
the systemic effect of tumor-secreted factors acting on the lung 
microenvironment in vivo, we administered tumor cell conditioned media (CM) 
intraperitoneally (i.p.) into mice. To be able to visualize the recruitment of bone 
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marrow-derived cells (BMDCs) to the lung microenvironment, we performed 
BM transplantation (BMT) of GFP+ BM into irradiated wild type (WT) syngeneic 
mice. The CM from metastatic LN4 cells significantly increased the recruitment 
of GFP+ BMDCs to the lungs, forming a premetastatic niche, as expected. 
Strikingly, CM from the metastasis-incompetent PC3 cell line similarly 
generated a GFP+ BM-derived premetastatic niche in the lungs (Figure 2.1a, 
b). Furthermore, the majority of recruited GFP+ cells were CD11b+ myeloid 
cells (Figure 2.1a, c). 
 
2-2.2. Poorly metastatic tumors induce Tsp-1 expression in the BM-derived 
cells recruited to the lung microenvironment. 
Having observed no difference in the cellular composition of the premetastatic 
lungs generated by metastasis-competent and incompetent tumors, we 
hypothesized that the BMDCs recruited to the lungs could harbor molecular 
differences that might explain the metastasis-resistant phenotype seen in 
metastasis-incompetent tumors. To explore this possibility further, we 
performed gene expression analysis of lungs from mice challenged with PC3 
CM or LN4 CM (Figure 2.2a). We focused our selection criteria on genes that 
encoded secreted proteins, which were negative regulators of metastatic 
outgrowth and were upregulated in PC3 CM-treated mouse lungs. Among the 
candidate genes, we selected thrombospondin-1 (Tsp-1) for further analysis, 
since it is a known inhibitor of angiogenesis and tumor progression, and since 
several regulators of Tsp-1 function were also upregulated in these lungs, 
including the CD47 receptor and ADAMTS1 (Figure 2.2a). Analysis of PC3 
CM-treated lungs validated that Tsp-1 was upregulated compared to LN4 CM- 
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Figure 2.1. Metastasis-incompetent tumor cells generate a bone marrow-derived myeloid cell premetastatic niche in the lungs.  (a) Representative immunofluorescence images showing recruitment of GFP+ BM-derived cells (green), and CD11b+ myeloid cells (red) in the lungs of mice treated with PC3 CM compared to LN4 CM. DAPI was used to label the nuclei of cells.  (b) Flow cytometry-based quantitation of recruited BM-derived GFP+ cells in lungs of mice treated with serum-free RPMI media (-), PC3 CM, or LN4 CM (n=3 per group). p= 0.047 (one-tailed Mann-Whitney U) between RPMI-treated and CM-treated mice.  (c) Flow cytometry-based quantitation of recruited CD11b+ myeloid cells in lungs of mice treated with serum-free RPMI media (-), PC3 CM, or LN4 CM (n=3 per group). p= 0.028 (one-tailed Mann-Whitney U) between RPMI-treated and CM-treated mice. 
(Data in Figure 2.1 generated in collaboration with Dr. R. Catena. Panels a, b, 
c generated by R. Catena.)  
a 
b c
Figure 2.1
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Figure 2.2. Metastasis-incompetent tumor cells upregulate Tsp-1 in the 
lung microenvironment.  
(a) A portion of the heat map obtained from hierarchical clustering of gene 
expression profiling of lungs from mice treated with LN4 CM or PC3 CM. Gene 
expression data was filtered using gene ontology so that only secreted 
proteins were considered.  Each row represents a gene that was differentially 
upregulated (≥ 1.5 fold) in PC3 CM-treated lungs and each column represents 
data from one animal. The relatively high expression is indicated in Red, while 
the relatively low expression is in Green. Tsp-1 is depicted by an arrow.  
(b) Quantitative RT-PCR analysis of Tsp-1 expression in lungs of RPMI-, PC3 
CM-, or LN4 CM-treated mice (n= 3 mice/ group).  
(c) Quantitation of Tsp-1+ cells/field in sections of lungs from LN4 CM- and 
PC3 CM-treated mice stained for Tsp-1, with DAPI as nuclear stain. p<0.001 
(one-tailed t test).  
(d) Representative immunofluorescence stain of Tsp-1 (white) in lungs of PC3 
CM- and LN4 CM-treated mice.  
For c and d, n=3 mice/ group; 2 sections per mouse, 10 fields per section. 
(Data in Figure 2.2 generated in collaboration with Dr. R. Catena. Panels c 
and d generated by R. Catena.)  
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treated lungs, both at the mRNA level by qRT-PCR, and at the protein level by 
immunostaining (Figure 2.2b-d). 
 
2-2.3. BM-derived CD11b+ Gr1+ myeloid cells are the major contributors of 
Tsp-1. 
Immunostaining for Tsp-1 revealed that Tsp-1 expression was mainly confined 
to the CD11b+ myeloid cell population in the lungs of PC3 CM-treated mice 
(Figure 2.3a). This finding was reproduced using a different myeloid cell 
marker, Gr1, in a breast cancer model, where CM from the weakly metastatic 
MDA-MB-231 cells induced upregulation of Tsp-1 in Gr1+ cells in lungs, 
compared to the highly metastatic MDA-LM2 cells (Figure 2.3b). To more 
accurately determine the cell population expressing Tsp-1 in the lungs, we 
sorted cells from mouse lungs treated with PC3 CM, and analyzed Tsp-1 
expression in the sorted populations by qRT-PCR. Tsp-1 was mainly 
contributed by the Gr1+ myeloid cell population, but not other hematopoietic 
populations or non-hematopoietic cells (Figure 2.4a). To further exclude the 
possibility that non-myeloid cell types express the Tsp-1 protein, we performed 
Western blot analysis on different cellular compartments from peripheral blood 
of wild type or Tsp-1-/- mice. Strikingly, the Gr1+ cells expressed abundant 
levels of Tsp-1 protein compared to Gr1- cells (Figure 2.4b), and as expected, 
Tsp-1 protein was absent in all cells sorted from Tsp-1-/- mice. Given that the 
Gr1+ cell population can be subdivided into Ly6G+ granulocytic myeloid cells, 
and Ly6Chigh myelomonocytic cells, we further analyzed Tsp-1 expression in 
these Gr1+ subpopulations and found that both subsets expressed Tsp-1 
(Figure 2.4c). These data suggest that BM-derived Gr1+ cells are the major 
source of Tsp-1 in the premetastatic microenvironments generated by  
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Figure 2.3. Metastasis-incompetent tumor cells induce Tsp-1 in myeloid 
cells recruited to the lungs.  
(a) Representative immunofluorescence staining of PC3 CM-treated mouse 
lungs depicting CD11b+ myeloid cell recruitment, and Tsp-1 protein expression 
in the CD11b+-staining cells. CD11b is in red; Tsp-1 is in magenta.  
(b) Representative immunofluorescence staining depicting Gr1+ myeloid cell 
recruitment, and Tsp-1 protein expression in the Gr1+-staining cells in lungs of 
mice treated with CM from MDA-MB-231 or its highly metastatic derivative 
MDA-LM2. CM was administered daily for 6 days and then lungs were 
analyzed. Gr1 is in white; Tsp-1 is in red.  
(c) Quantitation of Tsp-1 fluorescence intensity in lungs treated with MDA-MB-
231 CM (MDA CM) and MDA-LM2 CM (LM2 CM), described above, and 
stained for Tsp-1. (n=3 mice per group). 
(Data in Figure 2.3 generated in collaboration with Dr. R. Catena. Panel a 
generated by R. Catena.)  
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Figure 2.4. Tsp-1 is expressed by bone marrow-derived myeloid cells in the lungs.  (a) Quantitative RT-PCR analysis of Tsp-1 expression in different subsets of flow cytometry-sorted cells isolated from the lung. Of these, the CD45+ Gr1+ cells showed elevated Tsp-1 compared to CD45+ Gr1- cells or other CD45- cells. CD45+: hematopoietic cells; CD45- : non-hematopoietic cells; Gr1+: myeloid cells; Gr1-: non-myeloid hematopoietic cells; total: all lung cells.  (b) Western blot analysis of Tsp-1 levels in cellular hematopoietic compartments in the peripheral blood from WT mice and Tsp-1-/- mice show Gr1+ cells as a major source of Tsp-1. WBC: white blood cells.  (c) Quantitative RT-PCR analysis of Tsp-1 expression in different subsets of flow cytometry-sorted cells from the lung. Both subsets of Gr1+ cells, Ly6Chigh (monocytes) cells and Ly6G+ (neutrophils) cells express Tsp-1. CD3+: T-cells.  (d) Western blot analysis of Tsp-1 levels in lungs of mice after BM transplantation. Transplantation of Tsp-1-/- BM to WT recipients (Tsp-1-/- BM 
WT) rendered lungs devoid of Tsp-1. Conversely, transplantation of WT BM to Tsp-1-/- recipients (WT BM Tsp-1-/-) restored Tsp-1 expression in the lung. WT BM WT: transplantation of WT BM into WT recipients. Tsp-1-/- BM 
Tsp-1-/-: transplantation of Tsp-1-/- BM into Tsp-1-/- recipients. 
(Data in Figure 2.4 generated in collaboration with Dr. R. Catena. Panels b 
and d generated by R. Catena.)  
a b
c d
Figure 2.4
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metastasis-incompetent tumors. To highlight the BM-derived source of Tsp-1 
and exclude other non-bone marrow-derived stromal cells as possible Tsp-1 
sources, we performed BMT experiments and observed that Tsp-1 protein was 
absent in lungs of WT mice transplanted with Tsp-1-/- BM, but expression was 
restored in Tsp-1-/- mice transplanted with WT BM (Figure 2.4d). These 
results strongly indicate that BM-derived cells are the main source of Tsp-1 in 
the lungs induced by weakly metastatic tumors. 
 
2-2.4 Genetic deletion of Tsp-1 in the bone marrow results in increased 
metastasis. 
We hypothesized that upregulation of Tsp-1 by Gr1+ cells in the lungs could 
generate a metastasis-refractory microenvironment. To assess this possibility, 
we generated Tsp-1-/- BMT mice, i.e. irradiated WT mice that are transplanted 
with Tsp-1-/- BM, and determined their ability to form metastases compared to 
WT BMT controls, i.e. irradiated WT mice receiving WT BM. As expected, after 
BM engraftment, Tsp-1-/- BMT mice lack Tsp-1 protein and mRNA in 
peripheral blood leukocytes (Figure 2.5a, b). More importantly, when we 
evaluated the ability of luciferase-labeled Lewis lung carcinoma (LLC) cells to 
colonize the lung after tail vein injection, we observed accelerated metastatic 
outgrowth in Tsp-1-/- BMT mice compared to WT BMT mice by 
bioluminescence imaging (BLI) (Figure 2.5c). Western blot analysis of whole 
lung lysates revealed the complete absence of Tsp-1 protein in the lungs of 
Tsp-1-/- BMT mice (Figure 2.5d), despite the fact that Gr1+ cell recruitment to 
the lungs is unaltered (Figure 2.5e), reiterating that BMDCs are the major 
source of Tsp-1 in lungs in this metastatic setting. 
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Figure 2.5. BM-derived Gr1+ cells confer a metastasis-suppressive 
phenotype through the secretion of Tsp-1.  
(a) Western blot analysis for Tsp-1 expression in peripheral blood from WT 
mice transplanted with WT BM (WT  WT), and WT mice transplanted with 
Tsp-1-/- BM (Tsp-1-/-  WT).  
(b) Quantitative RT-PCR showing Tsp-1 expression levels in sorted Gr1+ cells 
from the peripheral blood of  Tsp-1-/-, Tsp-1-/- BMT, and WT BMT mice. Tsp-1 
expression was normalized to the internal control (GAPDH). RNA samples 
were pooled from 3 mice per group.  
(c) Left panel, Quantitation of pulmonary metastases in WT BMT mice and 
Tsp-1-/- BMT mice (n=7 per group).  BLI estimates were obtained at days 0, 5, 
8, 11, 14, 19 following tail vein injections of 1x105 LLC cells. p=0.0013 
between WT BMT and Tsp-1-/- BMT groups at day 19. Right panel, 
Representative BLI images showing metastasis suppression in WT BMT mice 
compared to Tsp-1-/- BMT mice at day 19.  
(d) Western blot analysis of Tsp-1 from the lungs of WT BMT mice and Tsp-1-/- 
BMT mice. Lung sample from Tsp-1-/- transgenic mice was used as a control. 
(e) Left panel, Representative immunofluorescence staining of Gr1+ myeloid 
cells (white) recruited to WT BMT and Tsp-1-/- BMT mouse lungs. Right panel, 
Quantitation of recruited Gr1+ myeloid cells in lungs based on 
immunofluorescence, depicting comparable recruitment of Gr1+ cells to WT 
BMT and Tsp-1-/- BMT lungs. (n=4 mice per group). 
(Data in Figure 2.5 generated in collaboration with Dr. R. Catena.) 
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To provide further evidence that BM-derived Tsp-1 plays an anti-metastatic 
role, we performed the reverse BMT experiments, where we transplanted WT  
BM into irradiated Tsp-1-/- recipients, or Tsp-1-/- BM into irradiated Tsp-1-/- mice 
as controls. Reintroducing WT BM into Tsp-1-/- recipients significantly 
suppressed metastasis (Figure 2.6a), and was accompanied by an increase in 
the expression of Tsp-1 in the lungs of these mice (Figure 2.4d), with restored 
Tsp-1 expression in their recruited Gr1+ cells (Figure 2.6b). These results 
reinforce the hypothesis that induction of Tsp-1 expression in Gr1+ cells can 
inhibit metastasis, and they suggest that intervening therapeutically to 
upregulate Tsp-1 in the lung myeloid cells could be a viable approach for the 
treatment of metastatic cancer. 
 
2-2.5. BM-derived Tsp-1 inhibits metastatic outgrowth through inhibition of 
tumor cell proliferation. 
Tsp-1 exerts its anti-tumorigenic activity via diverse mechanisms, including 
inhibition of angiogenesis, suppression of cell proliferation, and induction of 
apoptosis in both tumor and endothelial cells (Lawler and Lawler, 2012).  
Tsp-1-/- BMT mouse lungs exhibited increased tumor cell proliferation 
compared to WT BMT lungs, as determined by Ki67 staining (Figure 2.7a), 
while the tumor cell apoptotic index, measured by active caspase-3 staining, 
was unchanged (Figure 2.7b). Angiogenesis was also unaffected in this 
model (Figure 2.7c), and the lack of Tsp-1 in the lung BM cells did not alter 
the ability of tumor cells to seed the lungs (Figure 2.7d). Hence, induction of 
Tsp-1 in recruited Gr1+ cells suppresses metastasis by blocking the outgrowth 
of seeded tumor cells. 
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Figure 2.6. Restoring Tsp-1 in BM suppresses metastasis.  
(a) Left panel, Quantitation of pulmonary metastases in Tsp-1-/- mice 
transplanted with WT BM and Tsp-1-/- mice transplanted with Tsp-1-/- BM  (n=5 
per group).  BLI estimates were obtained following tail vein injections of 1x105 
LLC cells.  p=0.033 between the two group at day 30. Right panel, 
Representative bioluminescence images showing metastasis suppression in 
Tsp-1-/- mice transplanted with WT BM compared to Tsp-1-/- mice transplanted 
with Tsp-1-/- BM.  
(b) Representative immunofluorescence stains of recruited Gr1+ myeloid cells 
(white) and Tsp-1 (red) in WT BM  Tsp-1-/- and Tsp-1-/- BM Tsp-1-/- lungs. 
DAPI stains nuclei.  
(Data in Figure 2.6 generated in collaboration with Dr. R. Catena. Panel a 
generated by R. Catena.)  
a 
b 
Figure 2.6
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Figure 2.7. Tsp-1 suppresses tumor cell proliferation in the lungs. 
(a) Left panel, Representative Ki67 (magenta) immunofluorescence staining in 
lungs of WT BMT and Tsp-1-/- BMT mice. DAPI is used as a nuclear stain. 
Right panel, Quantitation of Ki67 staining in lungs of WT BMT and Tsp-1-/- 
BMT mice. (n=6 mice/ group). p= 0.003 (one-tailed t test).  
(b) Left panel, Representative active caspase-3 (magenta) 
immunofluorescence staining in lungs of WT BMT and Tsp-1-/- BMT mice. 
DAPI is used as a nuclear stain. Right panel, Quantitation of active caspase-3 
staining in lungs of WT BMT and Tsp-1-/- BMT mice. (n=6 mice/ group). p= 
0.09 (one-tailed t test).  
(c) Left panel, Representative immunofluorescence images showing vessel 
density in the metastases of WT BMT mice and Tsp1-/- BMT mice.  Endothelial 
cells are CD31+ (green). DAPI was used to stain nuclei. Right panel, 
Quantitation of vessels performed by evaluating sections from 6 mice per 
group (p=0.1249, two-tailed t test).   
(d) Left panel, Flow cytometric analysis of tumor cell seeding in WT BMT and 
Tsp1-/- BMT lungs 48 hrs following tail vein injection of mCherry-labeled LLC 
cells. Right panel, Flow cytometry-based quantitation of mCherry+ cells in 
lungs. (n= 4 mice per group). p=0.548 (two-tailed t-test). 
(Data in Figure 2.7 generated in collaboration with Dr. R. Catena. Panels a ,b, 
d generated by R. Catena.)  
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2-2.6. Tumor cell-derived prosaposin systemically stimulates Tsp-1 expression 
in the lung microenvironment. 
Based on our data, we speculated that the induction of Tsp-1 expression in the 
lung microenvironment could act as an anti-metastatic therapeutic approach. 
Previous studies have shown the antiangiogenic activity of ABT-510, a 
nonapeptide derived from Tsp-1 (Haviv et al., 2005); however, clinical trials 
have thus far not been able to prove its efficacy (Baker et al., 2008; 
Ebbinghaus et al., 2007; Markovic et al., 2007). This is why we believed that it 
would be necessary to induce full-length Tsp-1 in vivo to preserve all its 
inhibitory activity. To this end, we turned our focus to prosaposin (psap), a 
precursor of sphingolipid activator proteins, which was previously shown to 
stimulate the expression of Tsp-1 in human lung fibroblasts in vitro (Kang et 
al., 2009). 
To determine whether psap can induce Tsp-1 expression in recruited Gr1+ 
cells in mouse lungs, we utilized CM from MDA-MB-231 known to contain 
psap (Kang et al., 2009), and CM from MDA-MB-231 cells expressing psap-
shRNA. While MDA CM treatment stimulated Tsp-1 expression in lung Gr1+ 
cells, CM from MDA cell expressing psap-shRNA failed to induce Tsp-1 
(Figure 2.8a, b). Furthermore, orthotopically-injected LN4 cells 
overexpressing psap (LN4-psap) induced robust expression of Tsp-1 in 
premetastatic lungs compared to LN4 tumors, which are known not to secrete 
high levels of psap in their CM (Kang et al., 2009) (Figure 2.8c). These data 
suggest that psap secreted by tumor cells can systemically stimulate the 
expression of Tsp-1 in recruited Gr1+ myeloid cells in lungs.  
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Figure 2.8. Psap in tumor CM induces Tsp-1 expression in lungs. 
(a) Representative immunofluorescence staining of Gr1+ cells (white) and Tsp-
1 (red) in lungs of WT mice treated with MDA-MB-231 CM or CM from MDA-
MB-231 expressing psap-shRNA (MDA-MB-231 shPsap). DAPI is used as a 
nuclear stain.  
(b) Quantitation of Tsp-1 expression in stained sections from a. (n=3 mice/ 
group, 2 sections per mouse lung, 10 fields per section). Data presented as 
Mean ± SD. **, p= 0.002 (one-tailed t test).  
(c)  Western blot analysis of Tsp-1 in lungs of mice bearing LN4 or psap-
overexpressing LN4 (LN4-Psap) cells orthotopically injected in the prostate 
gland (n=3 mice per group). β-actin is a loading control. (Tsp-1 band runs as a 
smudge because the protein was extracted from formaldehyde-fixed samples, 
after reverse-crosslinking using the Qiagen Qproteome FFPE Tissue Kit). 
(Data in Figure 2.8 generated in collaboration with Dr. R. Catena. Panel c 
generated by R. Catena.)  
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2-2.7. The psap-derived pentapeptide DWLPK retains full Tsp-1-inducing 
activity. 
To verify if psap activity could be converted into a smaller agent more 
amenable to therapeutic systemic delivery, we set out to pinpoint the minimum 
region of psap capable of stimulating Tsp-1 expression in fibroblasts in vitro.  
We generated truncation mutants of psap, containing either the saposin A 
domain, saposin AB, saposin ABC, or saposin BCD, and expressed them in 
LN4 cells. CM from these cells was tested for its Tsp-1-inducing activity on  
WI-38 human fibroblasts in vitro, and it was clear that all truncation mutants 
that contained the saposin A domain induced Tsp-1 expression (Figure 2.9a). 
Thus, saposin A contains the Tsp-1-stimulating activity of psap. To determine 
shorter regions within saposin A that harbor Tsp-1-stimulating activity, we 
generated 20-amino acid overlapping peptides spanning the sequence of 
saposin A (Figure 2.9b), and observed that only the peptide spanning 
residues 31-50 of saposin A could induce Tsp-1 expression (Figure 2.9c). 
Based on the crystal structure of saposin A, the peptide lies in the hairpin 
region between helices 2 and 3 (Ahn et al., 2006).  Hence, we tested a 13-
amino acid cyclic peptide corresponding to residues 35-47, constrained by a 
disulfide bond at each end of the peptide. The cyclic peptide stimulated Tsp-1 
(Figure 2.9d). We then tested a 6-amino acid peptide, CDWLPK, 
corresponding to the first six residues of the cyclic peptide and found that it 
also was able to stimulate Tsp-1 (Figure 2.9f).  Finally, we tested six peptides 
from within the 6-amino acid sequence of CDWLPK and found that both a 5-
amino acid peptide (DWLPK) and a 4-amino acid peptide (DWLP) were able to 
stimulate Tsp-1 expression to an even greater extent than CDWLPK (Figure 
2.9f).  Finally, we assessed the 5-amino acid peptide in vivo by administering it  
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Figure 2.9. Deriving a peptide that retains the Tsp-1-inducing activity of 
Psap.  
(a) Schematic of Psap and its 4 saposin domains.  
(b) Western blot analysis of Tsp-1 induction in WI-38 human fibroblasts 
treated with CM from control LN4 cells (-), LN4 cells expressing an empty 
pLNCX vector (V), or LN4 expressing saposin domains A, AB, ABC, or BCD. 
(c) Amino acid sequence of human saposin A. The stem and hairpin regions 
are depicted above the sequence. The six conserved cysteines are in green. 
The boxed region represents the 20-amino acid peptide spanning residues 31-
50 of saposin A, capable of stimulating the expression of Tsp-1.   
(d) Western blot analysis of Tsp-1 expression in fibroblasts cultured with 7 
overlapping 20-amino acid peptides (1-20, 10-30, 21-40, 31-50, 41-60, 51-70 
and 61-81) spanning the length of saposin A.  
(e) Western blot analysis of Tsp-1 in WI-38 fibroblasts which were untreated  
(-) or treated with a cyclic 13-amino acid peptide corresponding to residues 35-
47 of saposin A.  
(f) Western blot analysis of Tsp-1 expression in WI-38 fibroblasts which were 
untreated (-) or treated with peptides derived from amino acids 35-40 of 
saposin A ranging from 3-6 amino acids in length (1=CDWLPK, 2=CDWLP, 
3=DWLPK, 4=DWLP, 5=CDW, 6=DWL).  
(g) Western blot showing Tsp-1 levels in mouse lung tissue following 
administration of media alone (-), LN4 CM (CM), or LN4 CM with 30 mg/kg/day 
psap peptide (DWLPK) for 6 days. 
(Data in Figure 2.9 was generated in the lab of Dr. Randolph Watnick at 
Children’s Hospital in Boston). 
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to mice in combination with LN4 CM and observed that it was able to stimulate 
Tsp-1 in the lungs of these mice (Figure 2.9g). 
 
2-2.8. DWLPK stimulates Tsp-1 expression in lung Gr1+ cells. 
After demonstrating that DWLPK retains Tsp-1-inducing activity of full-length 
psap in vitro and in vivo, we evaluated if it could equally influence Gr1+ cells in 
the lungs. To do that, we treated mice with LN4 CM to stimulate BMDC 
recruitment to the lungs, either alone or in combination with the DWLPK 
peptide (30 mg/kg). Treatments were administered daily via the intraperitoneal 
route, for 6 days. As expected, Gr1+ cell recruitment was comparable in both 
cases (Figure 2.10a, b); however, DWLPK induced significant expression of 
Tsp-1 in the recruited Gr1+ cells, as opposed to a peptide composed of the 
same amino acids in the scrambled sequence LPKDW (scrambled peptide) 
(Figure 2.10a, c). These results suggest that DWLPK peptide, by virtue of 
stimulating Tsp-1 in recruited Gr1+ cells in lungs, could generate a metastasis-
suppressive microenvironment. 
 
2-2.9. DWLPK inhibits metastasis through stimulation of Tsp-1 in Gr1+ cells. 
To evaluate if DWLPK-mediated Tsp-1 induction in lung Gr1+ myeloid cells 
can confer metastasis resistance, we introduced luciferase-labeled LLC cells 
via the tail vein into mice treated with either DWLPK peptide or scrambled 
control. Strikingly, treatment with DWLPK peptide dramatically reduced lung 
metastasis compared to the scrambled peptide, as measured by 
bioluminescence imaging (Figure 2.11a). Consistent with our previous 
observations, qRT-PCR analysis of different cell populations sorted from lungs  
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 Figure 2.10. Psap-derived DWLPK peptide induces Tsp-1 in Gr1+ myeloid cells recruited to the lungs.  (a) Representative immunofluorescence staining of Gr1+ myeloid cells (white) and Tsp-1 (red) in lungs of mice treated intraperitoneally with LN4 CM in combination with the scrambled-sequence peptide LPKDW (scr) or LN4 CM with the Psap-derived peptide DWLPK for 6 days. (b) Flow cytometry-based quantitation of Gr1+ cells in lungs of mice from the cohorts in a. (n= 3 mice/ group).  (c) Immunofluorescence-based quantitation of Tsp-1 expression in stained lung sections from Scr-treated or DWLPK-treated mice. (n= 3 mice /group, 4 sections/ mouse, 7-12 fields/ section). *, p=0.029 (one-tailed t-test). Mice were treated for 6 days with daily intraperitoneal injections of 30 mg/kg peptide + LN4 CM. 
(Data in Figure 2.10 generated in collaboration with Dr. R. Catena). 
a 
b c
Figure 2.10
45 
 
Figure 2.11. DWLPK suppresses metastasis and induces Tsp-1 in Gr1+ myeloid cells recruited to the lungs.  (a) Left Panel, Representative bioluminescence images showing pulmonary metastases, at day 29-post tumor inoculation, of WT mice treated with scrambled peptide (Scr) or DWLPK, and tail vein-injected with luciferase-labeled LLCs. Right panel, Quantitation of pulmonary metastases. BLI measurements were obtained at days 7, 11, 14, 18, 22, 26, and 29 after inoculation of LLC cells. The relative BLI values show total photon count over time. (n=5 per group). *, p=0.032 between Scr and DWLPK peptide-treated groups at day 29. Identical results were obtained in repeat experiments.  (b) Quantitative RT-PCR of Tsp-1 expression in cells sorted from lungs of Scr or DWLPK-treated mice. Total: total lung cells; CD45- : non-hematopoietic cells; CD45+ : hematopoietic cells; F4/80+ : macrophages; Gr1+ : myeloid cells. 
(Data in Figure 2.11 generated in collaboration with Dr. R. Catena). 
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revealed that Tsp-1 induction in response to DWLPK treatment was confined 
to Gr1+ myeloid cells and not Gr1- cells (Figure 2.11b). 
 
To confirm that the DWLPK-induced Tsp-1 expression in the BM compartment 
was responsible for the metastasis-suppressive phenotype observed, we 
generated Tsp-1 deletion in the bone marrow by transplanting Tsp-1-/- BM into 
WT mice, and used WT BMT mice as controls. Then both groups were treated 
with DWLPK and challenged with luciferase-labeled LLC cells via the tail vein. 
Notably, DWLPK treatment failed to suppress metastasis in Tsp-1-/- BMT mice, 
while it efficiently suppressed metastasis in WT BMT mice (Figure 2.12).  
Taken together, these data indicate that DWLPK peptide could have a 
therapeutic application for treating metastatic cancer via Tsp-1 induction in 
myeloid cells recruited to the lung microenvironment. 
 
2-2.10. Mechanism of psap-mediated Tsp-1 induction in Gr1+ cells 
Having established that psap and the psap-derived peptide DWLPK can 
induce Tsp-1 in Gr1+ myeloid cells in the lung microenvironment, we sought to 
determine the receptor via which psap signals in this context.   
The most commonly cited prosaposin receptor is the low density lipoprotein 
receptor-related protein 1 (LRP1). It is an endocytic receptor known to 
internalize secreted full-length psap, delivering it to the lysosome, where psap 
is processed into the individual saposins (Hiesberger et al., 1998). Despite the 
fact that no cytosolic signaling has been reported as a consequence of psap 
binding the LRP1 receptor, save the activation of the endocytic pathway, 
several reports have described signaling downstream of LRP1 in other 
contexts (Lillis et al., 2008). 
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Figure 2.12. Metastasis suppression by DWLPK requires bone marrow-
derived Tsp-1. Left Panel, Quantitation of pulmonary metastases in DWLPK 
peptide-treated WT BMT mice and Tsp-1-/- BMT mice (n=7 per group). BLI 
measurements were obtained at days 0, 5, 8, 14, and 19 following tail vein 
injections of 1x105 LLC cells.  p-values between WT BMT and Tsp-1-/- BMT 
groups are p=0.0049 and p=0.0084 at days 14 and 19, respectively (one-tailed 
t-test). Right panel, Representative bioluminescence images showing 
pulmonary metastases, at day 19 post-tumor inoculation, of DWLPK peptide-
treated WT BMT mice and Tsp-1-/- BMT mice tail vein-injected with luciferase-
labeled LLCs.  
(Data in Figure 2.12 generated in collaboration with Dr. R. Catena). 
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To evaluate the role of LRP1 in our model, we first deleted LRP1 in the 
myeloid cell compartment by making use of two transgenic mouse lines: the 
LRP1flox/flox mouse line, which has exons 1 and 2 of LRP1 flanked by LoxP 
sites (Rohlmann et al., 1996), and the LysM-Cre mouse line, which expresses 
Cre recombinase enzyme under the control of the myeloid-specific promoter of 
lysozyme M (LysM) (Clausen et al., 1999). Breeding these mouse lines 
generated two genotypes of interest to our study, both of which had LRP1f/f in 
the homozygous state, but had LysM-Cre either in the heterozygous state or 
the homozygous state. Flow cytometry analysis of LRP1 surface expression in 
peripheral blood Gr1+ cells revealed that around 20% of Gr1+ cells in WT mice 
expressed LRP1 receptor on their surface, whereas LRP1f/f LysM-Cre mice 
showed significant reduction in LRP1 expression on Gr1+ myeloid cells 
(Figure 2.13a, b). Notably, LRP1f/f mice homozygous for LysM-Cre (LysM-
Cre+/+) exhibited a more complete deletion of LRP1 on Gr1+ myeloid cells, 
compared to those with LysM-Cre in the heterozygous state (LysM-Cre+/-) 
(Figure 2.13a), prompting us to conduct all subsequent experiments using 
LRP1f/f LysM-Cre+/+ mice. Notably, LRP1f/f LysM-Cre+/+ mice and WT mice had 
a comparable composition of the major hematopoietic cell subpopulations in 
their peripheral blood (Figure 2.13c). 
 
2-2.11. LRP1 receptor is required for psap-mediated Tsp-1 induction in lung 
Gr1+ cells.  
To determine whether the LRP1 receptor is required for psap-mediated Tsp-1 
induction in vivo, we treated WT and LRP1f/f LysM-Cre+/+ mice with psap-
containing PC3 CM intraperitoneally for six days, then analyze the lungs for 
Tsp-1 protein expression. Immunofluorescence staining revealed that, as  
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Figure 2.13. Myeloid-specific inducible knockout of LRP1.  (a) Flow cytometry-based quantitation of the percentage of LRP1+ cells within the Gr1+ cell population, in peripheral blood from WT, LRP1f/f LysM-Cre+/-, and LRP1f/f LysM-Cre+/+ mice. (n= 3 mice/ group). Data presented as Mean ± SD. (b) Representative flow cytometry plots depicting the percentage of LRP1+ cells within the Gr1+ cell population in peripheral blood from WT and LRP1f/f LysM-Cre+/+ mice. We first gated Gr1+ myeloid cells within the total CD45+ hematopoietic cell population in the blood, followed by gating LRP1+ cells within the Gr1+ cell population. Blood samples from 3 mice per genotype were analyzed. Results are presented as Mean ± SD.  (c) Flow cytometry-based quantitation of hematopoietic cell composition in peripheral blood of WT and LRP1f/f LysM-Cre+/+ mice. CD3+: T cells; CD11b+: myeloid cells; B220+: B cells; Gr1+: myeloid cells; CD45+: total hematopoietic cells. 
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expected, LRP1f/f LysM-Cre+/+ lungs lacked LRP1 expression in Gr1+ myeloid 
cells (Figure 2.14a). More importantly, LRP1f/f LysM-Cre+/+ lungs showed 
significantly lower induction of Tsp-1 in response to psap-containing medium 
compared to WT lungs, by immunofluorescence staining, despite the 
comparable recruitment of Gr1+ myeloid cells to these lungs (Figure 2.14a, b). 
Similarly, LRP1f/f LysM-Cre+/+ mice treated with DWLPK peptide exhibited 
lower levels of Tsp-1 protein in their whole lung lysates compared to WT mice 
(Figure 2.14c). These results suggest that LRP1 receptor on Gr1+ myeloid 
cells responds to psap/DWLPK and relays signals leading to Tsp-1 induction. 
 
2-3. DISCUSSION  
Our study demonstrates, for the first time, the ability of metastasis-
incompetent primary tumors to systemically reprogram BM-derived myeloid 
cells in the lung microenvironment, inhibiting metastasis. Prior to our study, 
research on metastasis suppression had been focused on tumor cell intrinsic 
suppressors of metastasis, such as KISS1, MKK4, p38, and MKK7 (Cook et 
al., 2011; Shevde and Welch, 2003). Here, we have identified a mechanism 
whereby metastasis-incompetent primary tumors, by virtue of secreting 
prosaposin, systemically alter the microenvironment at the distal organ, 
rendering it metastasis-suppressive (Figure 2.15). 
Though initially surprising, we demonstrated that tumors with low metastatic 
potential are as efficient as highly metastatic tumors at generating a 
premetastatic niche, composed primarily of recruited BM-derived CD11b+ Gr1+ 
myeloid cells (Figure 2.1a, b). More interesting was the fact that the niches 
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Figure 2.14. Myeloid-specific knockout of LRP1 blocks Psap-mediated 
Tsp-1 induction in Gr1+ myeloid cells.  
(a) Representative immunofluorescence staining of Gr1+ myeloid cells (white) 
and the expression of LRP1 (green) and Tsp-1 (red) in the lungs of WT and 
LRP1f/f LysM-Cre+/+ mice treated with Psap-containing PC3 CM for 6 days. 
DAPI stains nuclei. White arrows point to cells that show colocalization of Gr1, 
LRP1, and Tsp-1.  
(b) Immunofluorescence staining-based quantification of Gr1+ cells recruited to 
lungs of WT and LRP1f/f LysM-Cre+/+ mice treated with PC3 CM (n= 3 mice per 
group, 1 section per mouse, 7-8 fields per sections). p=0.198 (two-tailed t 
test). (c) Western blot analysis of Tsp-1 in lungs of WT and LRP1f/f LysM-
Cre+/+ mice treated with DWLPK for 6 days. β-actin is a loading control. 
 
 
 
 
Figure 2.14
a 
b c
52 
 
        
  Figure 2.15. Proposed model. Metastasis-incompetent primary tumors secrete prosaposin, which systemically acts on bone marrow-derived myeloid cells recruited to the lungs, inducing their expression of the anti-tumorigenic factor Tsp-1. This suppresses metastasis by blocking tumor cell proliferation. 
 
 
 
 
 
 
 
Figure 2.15
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generated in each case were molecularly different, with metastasis-
incompetent tumors systemically upregulating the expression of the anti-
tumorigenic factor Tsp-1 in the recruited myeloid cells (Figure 2.2). This is 
especially significant since BM-derived myeloid cells in the premetastatic niche 
are known to promote metastasis by supporting angiogenesis, enhancing 
tumor proliferation, and driving mesenchymal-to-epithelial transition (Gao et 
al., 2008, 2012; Shojaei et al., 2007). However, under conditions in which the 
primary tumor is poorly metastatic, the same myeloid cells are converted into 
metastasis-inhibitory cells by virtue of their Tsp-1 expression. This scenario  
underscores the plasticity of BM-derived cells and the large impact that tumor-
derived systemic factors have on shaping the distant organ microenvironment 
depending on different contexts. 
Moreover, the fact that metastasis suppression was abrogated in Tsp-1-/- BMT 
mice highlights the requirement for Tsp-1 expression in recruited BM-derived 
Gr1+ myeloid cells. In addition, we have uncovered a novel mechanism in 
which Gr1+ cells in the lungs are the major source of Tsp-1, leading to 
metastasis inhibition. 
 
Based on a previous study conducted by our collaborators identifying the 
tumor-secreted factor prosaposin with anti-metastatic activity (Kang et al., 
2009), we derived the pentapeptide DWLPK. This allowed us to test its 
potential use as a therapeutic agent to suppress metastasis. DWLPK exhibited 
significant anti-metastatic activity, and it induced Tsp-1 expression in Gr1+ 
cells in the lung microenvironment.  
Another therapeutic, the Tsp-1-derived nonapeptide, ABT-510, is currently in 
phase II clinical trials for the treatment of advanced metastatic tumors. 
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Although ABT-510 is derived from the second type-1 repeat of Tsp-1, with 
known antiangiogenic activity, and it exhibits antiangiogenic activity in vitro 
(Haviv et al., 2005), it has failed to enhance patient outcomes in clinical trials 
(Baker et al., 2008; Ebbinghaus et al., 2007; Markovic et al., 2007). We 
believe that DWLPK will be a more successful anti-metastatic therapeutic 
agent than ABT-510 because, contrary to ABT-510, DWLPK can induce the 
expression of full-length Tsp-1 with all its domains and functions intact. 
The next step for optimizing DWLPK function as a therapeutic agent for 
advanced metastatic cancer will be to chemically modify it to increase its half-
life in circulation, increase its bioavailability, and reduce the rate of its 
clearance. This will be further discussed in Chapter Four. 
Based on data generated with myeloid-specific LRP1 knockout mice, psap 
signals via the LRP1 receptor on myeloid cells to induce Tsp-1 expression. 
These results, for the first time, describe a signaling event involving psap and 
LRP1, where LRP1 does not merely act as an endocytic receptor for psap. 
Signaling events described downstream of LRP1 have been sparse, but have 
included activation by PDGF-BB in conjunction with PDGFR-β, intracellular 
signaling following Tsp-1-calreticulin binding leading to focal adhesion 
disassembly, and possible transcriptional regulation via the cleaved LRP1 
intracellular domain (Kinoshita et al., 2003; May et al., 2002).  Studies are 
underway to determine the domains within LRP1 that are required for Tsp-1 
induction in response to psap, as well as the downstream signaling cascade 
activated.  In addition, it would be interesting to evaluate whether psap or 
DWLPK signaling downstream of LRP1 can also suppress metastasis. This is 
discussed in greater detail in Chapter Four. 
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In conclusion, we have established the novel mechanism whereby tumors with 
low metastatic potential systemically impinge upon the distant organ 
microenvironment, rendering it less conducive to metastatic outgrowth. Our 
study further highlights the plasticity of myeloid cells in the lung 
microenvironment and their ability to respond to primary tumor-derived factors, 
shaping the outcome of metastatic progression. 
 
2-4. MATERIALS AND METHODS 
2-4.1. Mice and cell lines  
All animal work was conducted in accordance with a protocol approved by the 
Institutional Animal Care and Use Committee. Wild type C57BL/6J, GFP 
transgenic C57BL/6-Tg (CAG-EGFP) 1Osb/J, LRP1f/f transgenic B6;129S7-
Lrp1tm2Her/J, and LysM-Cre transgenic B6.129P2-Lyz2tm1(cre)Ifo/J mice were 
obtained from The Jackson Laboratory (Bar Harbor, Maine). CB-17 SCID mice 
were obtained from Charles River (Wilmington, MA). Tsp-1 knockout mice in 
the C57BL/6J background, a kind gift from Dr. Shahin Rafii (Weill Cornell 
Medical College, NY) were bred in the lab and genotyped according to 
standard protocols.  
The human prostate cancer cell lines PC3 and PC3M-LN4 are previously 
described (Kang et al., 2009). The human breast cancer cell lines MDA-MB-
231 and MDA-MB-LM2 are described previously (Ryu et al., 2011). The 
murine Lewis lung carcinoma cell line LLCs/D122 (provided by Lea Eisenbach, 
Wiesmann Institute of Science, Rehovot, Israel) stably expressing RFP and 
firefly luciferase (Gao et al., 2008) was cultured in DMEM supplemented with 
10% fetal bovine serum (FBS). PC3, LN4, and MDA-MB-231 cell lines were 
obtained from ATCC and cultured in RPMI supplemented with 10% FBS. 
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2-4.2. Bone marrow isolation and transplantation 
BM transplantation was performed by injecting 1x107 total BM cells into the 
retro-orbital sinus (Yardeni et al., 2011) of lethally irradiated (900 rads) 8-week 
old C57BL/6 female mice. BM cells were harvested by flushing femurs and 
tibias of donor animals, including C57BL/6 Tg (ACTB-EGFP) 1Osb/J GFP 
transgenic, C57BL/6 Wild-type, or C57BL/6 Tsp-1-/- mice, using 1X phosphate 
buffer saline (PBS). After 4 weeks of BM engraftment, reconstitution efficiency 
was monitored by flow cytometry of hematopoietic cell populations in the 
peripheral blood, as well as Western blot analysis of peripheral blood for 
absence of Tsp-1 protein in mice transplanted with Tsp-1-/- BM. 
 
2-4.3. Conditioned medium (CM) experiments  
PC3 or PC3M-LN4 cells were cultured in RPMI with 10% FBS.  5x106 cells 
were then subcultured in 7 mL of serum-free medium in 10 cm plates for 24 
hours in order to generate CM. Harvested media was centrifuged and filtered 
through 0.22 μm pore-size filters to remove any cells or cell debris. 
Wild-type BMT and Tsp-1−/− BMT C57BL/6J mice were pretreated with 200 μL 
serum-free CM from PC3 or LN4 cells or serum-free RPMI media daily for 6 
days via intraperitoneal (i.p.) injection.  
 
2-4.4. Peptide generation and administration  
Prosaposin truncation mutants were created by cloning the regions of 
prosaposin generated by PCR amplification using the following strategy: 
Saposin A, Saposin AB, and Saposin ABC were all created using the same 5’ 
primer: ggcggcgtcgacATGTACGCCCTCTTCCTCC and the following 3’ 
primers: saposin A: ggcgcctctagaAGAGACTCGCAGAGGTTGAG; saposin 
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AB: ggcgcctctagaACCTCATCACAGAACCC; saposin ABC: 
ggcgcctctagaGCCAGAGCAGAGGTGCAGC.  The PCR products were then 
cleaved with Xba1 and Sal1 and cloned into pCMVneo.   
The psap truncation constructs were then used to transfect PC3M-LN4 using 
the Fugene6 transfection reagent and protocol (Roche). CM of transfected 
cells was harvested 48 hours after transfection and used to treat WI-38 lung 
fibroblasts for 16 hours.  After CM treatment, fibroblasts were harvested and 
lysed, and Tsp-1 protein expression analyzed by Western blot as previously 
described (Kang et al., 2009). 
The seven 20-amino acid peptides spanning the length of saposin A were 
comprised of the following sequences:  
1-20- SLPCDICKDVVTAAGDMLKD; 11-30- VTAAGDMLKDNATEEEILVY;  
21-40- NATEEEILVYLEKTCDWLPK; 31-50- LEKTCDWLPKPNMSASCKEI; 
41-60- PNMSASCKEIVDSYLPVILD; 51-70- VDSYLPVILDIIKGEMSRPG;  61-
81- IIKGEMSRPGEVCSALNLCES. All peptides were synthesized by 
Anaspec, Inc (Fremont, CA).  The 13 amino acid cyclic peptide was comprised 
of the following sequence: CDWLPKPNMSASC.    
 
For in vitro analysis of peptide activity, WI-38 lung fibroblasts were treated with 
peptide for 16 hours at a concentration of 5 μg/mL. The cells were then 
harvested and lysed for Tsp-1 Western blot analysis as previously described 
(Kang et al., 2009).   
 
The in vivo analysis of peptide activity was performed by treating 8-week old 
C57BL/6 mice with either 300 μL of PC3M-LN4 CM alone or in combination 
with peptide, diluted in PBS, at a dose of 30 mg/kg/day via intraperitoneal 
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injection for six days.  After six days the mice were euthanized by cervical 
dislocation under isofluorane anesthetic. The lungs were harvested, lysed, and 
analyzed for protein expression. 
For metastasis experiments, the psap peptide DWLPK and a scrambled 
peptide LPKDW were synthesized by AnaSpec (Fremont, CA). Peptide diluted 
in saline was administered to mice (30 mg/kg) via intraperitoneal injection on a 
daily basis for six days before LLC tumor cell tail vein injection and until the 
end of the metastasis assays. 
 
2-4.5. Metastasis assay, bioluminescence imaging, and analysis  
For experimental metastasis, 8-week old C57BL/6 mice were injected via tail 
vein with 1 x 105 luciferase-labeled LLC cells. Pulmonary metastases were 
monitored by live animal bioluminescence imaging (Xenogen) once per week.  
For in vivo determination of the metastatic burden of luciferase-labeled LLCs, 
mice were anaesthetized and injected intraperitoneally with 75 mg/kg of D-
luciferin (100 μL of 30 mg/mL in PBS). Metastatic growth was monitored over 
time using bioluminescence imaging performed with mice in a supine position 
5 min after D-luciferin injection with a Xenogen IVIS system coupled to Living 
Image acquisition and analysis software (Xenogen). For BLI plots, photon flux 
was calculated for each mouse by using the same circular region of interest 
encompassing the thorax of the mouse.  
 
For orthotopic prostate cancer cell injections, 2 x 106 viable LN4 or LN4-psap 
cells were injected into the prostate gland of CB-17 SCID mice. Primary tumor 
size was monitored using a caliper. When tumor size reached 1 cm3, lungs 
were collected to determine Tsp-1 protein levels. 
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2-4.6. Immunofluorescence and microscopy  
Animals were euthanized at the end of experiments, and lungs were quickly 
perfused by injecting 5 mL of cold PBS through the right ventricle of the heart.  
One part of the lung from each animal was fixed in 3.7% formalin and the 
other part was sorted by flow cytometry for RNA extraction or used for protein 
extraction. 
For microscopy, following formalin fixation, tissues were cryoembedded in 
Tissue-Tek O.C.T. embedding compound (Electron Microscopy Sciences).  
Sections (10 μm) were washed 3 times in PBS and incubated in 
blocking/permeabilization buffer (PBS, 5% BSA, 0.25% Triton X-100).  
Sections were then incubated with labeled primary antibodies against Gr1 
(Clone RB6-8C5, BD Pharmingen), CD11b (Clone M1/70, BD Pharmingen), 
Ki-67 (abcam), Tsp-1 (Ab-4 or Ab-11 from LabVision), Active-Caspase-3 (BD 
Pharmingen), and LRP1 (clone EPR3724, abcam) for 2 hours at room 
temperature. Typically primary antibodies were either commercially conjugated 
to fluorescent dyes, or manually conjugated to Alexa Fluor dyes (Alexa 488, 
Alexa 568, Alexa 647 and Alexa 750) using antibody-labeling kits (Invitrogen) 
performed as per manufacturer’s instructions and purified over BioSpin P30 
Gel (Biorad). Primary antibodies were diluted in blocking/permeabilization 
buffer at a dilution of 1:100. After primary antibody incubation, sections were 
rinsed 5 times with PBS, counter-stained with DAPI and mounted in Prolong 
Gold-antifade reagent for epifluorescence microscopy analysis. For LRP1 
staining, after primary antibody incubation, secondary anti-rabbit antibody 
conjugated to Alexa Fluor-488 was used at a dilution of 1:100 for 1 hour.  
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Lung sections were also stained with hematoxylin and eosin for morphometric 
determinations. GFP positive cells were detected by their intrinsic 
fluorescence.  
Fluorescence images were obtained using a computerized Zeiss fluorescence 
microscope (Axiovert 200M), fitted with an apotome and a HRM camera. 
Images were analyzed using Axiovision 4.8 software (Carl Zeiss Inc.).  
 
2-4.7. Flow cytometry and cell sorting 
To obtain single cell suspensions, lungs were minced and then digested in 
collagenase/DNase mix (Roche) for 30 min at 37ºC. Cells were washed, 
strained and resuspended in FACS staining buffer (PBS + 2 mM EDTA, 1% 
BSA). For analysis of peripheral blood, blood was collected from the tails of 
mice in anti-coagulant buffer (PBS with 5 mM EDTA). Red blood cells were 
eliminated by incubation in RBC Lysis Buffer (5 Prime) for 10 min on ice. Cell 
suspensions were pre-blocked in FACS buffer plus Fc block (CD16/CD32, 
1:100, BD Biosciences Pharmingen) and then incubated with the following 
primary antibodies:  rat IgG2ακ and IgG2αβ isotype control (BD Pharmingen), 
Ly6G (Clone 1A8, BD Pharmingen), Ly6C (Clone HK1.4), Gr1 (Clone RB6-
8C5, Biolegend), CD11b (clone M1/70, BD Pharmingen), CD45 (Clone 30-F1, 
Biolegend), CD3 (Clone 17A2, Biolegend), and B220 (Clone RA3-6B2, 
Biolegend). LRP1 antibody (clone 5A6, abcam) was conjugated to Alexa 
Fluor-488 dye. SYTOX blue (Invitrogen) was added and incubated for 5 
minutes at room temperature in each cell staining tube to facilitate the 
elimination of dead cells by flow cytometry.   
Labeled cell populations were measured by LSRII flow cytometer coupled with 
FACSDiva software (BD Bioscience). Flow cytometry analysis was performed 
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using a variety of controls including isotype antibodies, single color control 
samples, and unstained samples for determining appropriate gates, voltages, 
and compensations required in multivariate flow cytometry. For sorting, 
targeted cell populations were gated within FACSDiva software and sorted by 
Aria II sorter (BD Bioscience). For sorting, SYTOX blue-negative was utilized 
to remove dead cells. CD45-, CD45+ Ly6Chigh, CD45+ Ly6G+, CD45+ Gr1+, 
CD45+ Gr1-, CD45+ F4/80+, and CD45+ CD3+ subsets were isolated. Cells 
were quickly processed for RNA isolation using PicoPure RNA isolation kit 
(Arcturus). 
 
2-4.8. Quantitative RT-PCR analysis  
Total RNA from flow cytometry sorted cells was extracted using the PicoPure 
RNA extraction kit (Arcturus) following the manufacturer’s protocol. RNA was 
converted to cDNA using qScript™ cDNA supermix (Quanta Biosciences). Q-
PCR was performed with primers and iQTM SYBER Green master mix 
(Biorad, Hercule, CA). Each sample was duplicated to minimize pipetting error. 
A standard protocol of initial denaturing at 95°C for 10 min, 40 cycles of 95°C 
for 10 sec, 60°C for 30 sec, and 72°C for 30 sec, followed by final extension at 
72°C for 5 min and melt curve analysis was applied on a BioRad CFX96 Real 
Time System (BioRad) coupled with Bio-Rad-CFX Manager software. The 
relative abundance of each transcript compared with the control was 
calculated utilizing the delta-Ct method.  
The primer sequences used for RT-PCR were:  
Mus-GAPDH-for: CATGGCCTTCCGTGTTCCTA 
Mus-GAPDH-rev: GCGGCACGTCAGATCCA 
Mus-Tsp-1-for: CTTGAGGCAGATGAAGAAGACC 
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Mus-Tsp-1-rev: ACTGACACCACTTGTTGCTTCC 
 
2-4.9. Western blot analysis  
Cells were homogenized in lysis buffer (BioRad) containing protease inhibitors 
(Roche Applied Science). Samples were boiled in 1x SDS sampling buffer with 
10% β-mercaptoethanol, and loaded onto 4-12% gradient Bis-Tris NuPAGE 
gels (Invitrogen). Western blotting was performed using antibodies specific for 
Tsp-1, (clones Ab-4 and Ab-11, Labvision), LRP1 (clone EPR3724, abcam), 
and β-actin (Sigma-Aldrich).  
 
2-4.10. Gene expression profiling 
Mice were administered intraperitoneally with 200 μL of PC3-CM or LN4-CM 
daily for 8 days.  Lungs were collected at day 9 and used for harvesting RNA. 
RNA quality and integrity was assessed by a bioanalyzer (Agilent). RNA was 
converted to biotinylated cDNA, and hybridized to Mouse Exon Affymetrix 
Gene ST 1.0 chips (Affymetrix, Santa Clara, CA) for gene expression analysis. 
Microarray data was processed using Affymetrix Expression Console™ 
software (Affymetrix, CA) with RMA (Robust Multi-array Analysis) 
normalization. The data was normalized by Z-score calculations using 
standard deviation, and hierarchical clustering was performed on 1846 genes 
with gene ontology annotation describing them as being extracellular 
(secreted), using software from Spotfire. The files for this experiment are 
available at the NCBI´s public microarray repository under the link:  
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE44459 
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2-4.11. Statistical Analysis  
Results were expressed as mean ± SEM depicted by error bars, unless 
otherwise noted. Analyses of different treatment groups were performed using 
the Mann-Whitney U or Student t tests using the GraphPad Prism statistics 
software. p values < 0.05 were considered significant.  
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CHAPTER THREE 
LUNG INFLAMMATION PROMOTES METASTASIS VIA TSP-1 
DEGRADATION. 
 
3-1. INTRODUCTION 
Clinical and animal model studies have suggested a strong interplay between 
inflammation and primary tumor progression (Ben-Neriah and Karin, 2011). 
However, less is known about the contribution of inflammation to metastatic 
outgrowth in distant organs. Accumulating evidence has demonstrated that 
primary tumors generate metastasis-promoting premetastatic niches in distant 
metastatic organs that exhibit features of inflammation. For instance, primary 
tumors systemically induce elevated levels of the chemoattractants S100A8 
and S100A9 in the lungs, which in turn stimulate the expression of serum 
amyloid A (SAA) 3, leading to further recruitment of myeloid cells and the 
activation of NF-κB signaling through TLR4, resulting in the amplification of 
inflammatory responses (Hiratsuka et al., 2006, 2008). Identifying mechanisms 
by which primary tumor-derived premetastatic niches contribute to tumor 
outgrowth is an area of active investigation; however, little is known about the 
mechanisms by which external inflammation in the lungs can impact 
metastasis of extapulmonary neoplasms. 
 
The lung, which is susceptible to inflammatory insults, is a frequent site of 
metastasis from a variety of extrapulmonary neoplasms. For example, in a 
mouse model of autoimmune arthritis, increased recruitment of inflammatory 
neutrophils and macrophages in the lungs was associated with increased 
breast cancer metastasis to the lungs (Das Roy et al., 2009). Similarly, 
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external insults, including smoke-inhalation and bacterial infections induced 
metastasis-conducive microenvironments in the lung (Murin et al., 2004; Smith 
and Kang, 2013). The mechanisms by which inflammation contributes to tumor 
outgrowth in distant metastatic organs have remained underexplored.   
 
We hypothesized that externally-induced lung inflammation could function in a 
manner similar to that of a premetastatic niche and predispose the lungs to 
enhanced metastasis. In this chapter, we have explored mechanisms of 
inflammation-driven metastatic progression. We demonstrate that lung-specific 
inflammation was associated with recruitment of neutrophils, which 
degranulated to release the serine proteases, neutrophil elastase (NE) and 
cathepsin G (CG). Importantly, NE and CG degraded the anti-tumorigenic 
factor thrombospondin-1 (Tsp-1), rendering the lung microenvironment 
conducive to metastatic outgrowth. Genetic and pharmacological inhibition of 
both proteases suppressed inflammation-mediated metastatic outgrowth, 
providing further evidence that neutrophil-derived proteases are responsible 
for generating a tumor-promoting microenvironment, and demonstrating a 
novel mechanism of Tsp-1 regulation in the metastatic organ. 
 
3-1.1. Common forms of lung inflammation in humans 
1- Acute lung injury (ALI) 
Acute lung injury (ALI) as a result of sepsis is a major cause of mortality (Kao 
et al., 2007). ALI, and its more severe manifestation, acute respiratory distress 
syndrome (ARDS), are characterized by a significant infiltration of neutrophils 
into the lungs, accompanied by the expression of pro-inflammatory cytokines 
and damage to the lungs (Goodman et al., 1996). More specifically, ALI is 
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characterized by an acute inflammatory phase followed by a chronic 
fibroproliferative phase. The acute phase consists of increased epithelial and 
vascular permeability, as well as impaired clearance of the excess alveolar 
fluid, leading to an increase in extravascular lung fluid and edema. This is also 
accompanied by pronounced neutrophil infiltration, protease activation, and an 
increased expression of pro-inflammatory cytokines. At later stages, a fibrotic 
response occurs, characterized by the deposition of collagen types I and III 
and marked fibroblast proliferation, accompanied by the destruction of the 
alveolar basement membrane (Matute-Bello et al., 2008; Pittet et al., 1997). 
 
Bacterial lipopolysaccharide (LPS) is the main component of sepsis-caused 
ALI (Brigham and Meyrick, 1986). LPS causes damage to the lung epithelium 
and endothelium, associated with increased neutrophil influx to lungs and 
increase in free oxygen radicals (Brigham and Meyrick, 1986; Güngör et al., 
2010a; Haegens et al., 2009; Jeyaseelan et al., 2004). LPS induced elevated 
levels of nitric oxide (NO), inducible nitric oxide synthase (iNOS), and the pro-
inflammatory cytokines tumor necrosis factor α (TNFα) and interleukin-1β (IL-
1β), as well as a neutrophil chemoattractants CXCL1, MIP-1α, MIP-2, and 
CXCL5 (Haegens et al., 2009; Jeyaseelan et al., 2004; Su et al., 2012; Wang 
et al., 1999). Furthermore, inhibition of iNOS attenuated the release of NO and 
cytokines, and inhibited the damage causing ALI (Su et al., 2007, 2012). 
 
2- COPD and emphysema 
One manifestation of chronic inflammation in lungs is chronic obstructive 
pulmonary disorder (COPD). COPD is characterized by an elevated and 
persistent inflammatory infiltrate, composed of neutrophils, macrophages, and 
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lymphocytes in the airways and parenchyma, increased deposition of collagen 
in airway walls characteristic of fibrosis, disruption of elastin fibers, finally 
leading to loss of alveolar septa, resulting in emphysema (Jeffery, 1998). The 
pro-inflammatory cytokine IL-1β is significantly elevated in the lungs of 
patients with COPD, along with TNFα, IL-6, and IL-8 (Chung, 2001). 
Using transgenic mice that expressed IL-1β in the lung epithelium in an 
inducible manner, the effects of IL-1β-driven lung inflammation were 
determined. IL-1β expression in lung epithelium caused infiltration of 
neutrophils and macrophages, enlargement of alveoli reminiscent of 
emphysema, fibrosis in airway walls characterized by collagen deposition, and 
upregulation of neutrophil chemoattractants CXCL1 and CXCL2, as well as the 
proteases MMP9 and MMP12 (Lappalainen et al., 2005). These observations 
suggest that IL-1β expression in the lung epithelium was sufficient to generate 
a state similar to human COPD.  
 
IL-1 pro-inflammatory cytokine is involved in initiating inflammation and 
maintaining it. Activation of TLR signaling, leading to NF-κB signaling, induces 
the expression and synthesis of inactive pro-IL-1β that gets activated upon 
cleavage by the IL-1β-converting enzyme (ICE), also known as caspase-1 
(Dinarello, 1996; Takeuchi and Akira, 2010), or by MMP9 (Schönbeck et al., 
1998). IL-1β is produced by monocytes and macrophages primarily, and also 
by neutrophils, T cells, fibroblasts, and epithelial cells (Dinarello, 1996). It 
contributes to the mobilization of neutrophils from the bone marrow, and it 
promotes the synthesis of other cytokines, including TNFα, IL-6, IL-8, and 
granulocyte monocyte colony-stimulating factor (GM-CSF) (Chung, 2001). 
Furthermore, IL-1β induces the expression of intercellular adhesion molecule -
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1 (ICAM-1) and vascular cell adhesion molecule -1 (VCAM-1) on endothelial 
cells, allowing the adhesion of neutrophils to endothelial cells during 
inflammation (Chung, 2001). 
 
3-1.2. Pattern recognition receptors and LPS signaling 
1- Pattern recognition receptors 
Pattern recognition receptors (PRRs) on the surface of immune cells allow the 
response to microbial pathogens or damaged host cells. They do that by 
recognizing pathogen-associated molecular patterns (PAMPs), conserved 
molecular structures on different microbial species, and damage-associated 
molecular patterns (DAMPs), which are endogenous molecules released by 
damaged host cells. Signaling downstream of PAMP- or DAMP-activated 
PRRs leads to the induction of pro-inflammatory mediators, such as IL-1β, 
TNFα, IL-6, and type I interferons (IFNs) (Takeuchi and Akira, 2010). 
 
The best characterized PRR family is the TLR family. It consists of 10 
members identified in humans and 12 in mice. TLRs sense pathogens outside 
the cell, as well as inside endosomes and lysosomes (Akira et al., 2006). 
Different TLRs can recognize different pathogen-derived and self-derived 
molecular patterns. For instance, TLR1, TLR2, and TLR6 recognize lipids, 
while TLR7, TLR8, TLR9 recognize nucleic acids. Interestingly, TLR4 is the 
only receptor that can recognize a diverse array of structurally unrelated 
ligands, including LPS, some self-derived heat shock proteins, and some viral 
antigens. TLR expression is regulated in response to pathogens, other 
environmental stressors, or cytokines, and TLRs are expressed on a number 
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of immune cells, including macrophages, dendritic cells, neutrophils, B cells, 
and some T cells (Akira et al., 2006). 
 
2- Bacterial lipopolysaccharide (LPS) signals through TLR4. 
LPS, also called endotoxin, is a component of the outer membrane of Gram-
negative bacteria, and is a known cause of septic shock. LPS is structurally 
composed of polysaccharides of the O-antigen and the core domain, and an 
amphipathic lipid A (Raetz and Whitfield, 2002). Lipid A is the immunogenic 
domain of LPS. An important determinant of LPS inflammatory activity is the 
number of lipid chains constituting lipid A, where lipid A with six lipid chains 
has optimal immunogenic activity, and one with five lipid chains is ~ 100-fold 
less active (Teghanemt et al., 2005). LPS is recognized by TLR4 in a complex 
with myeloid differentiation protein 2 (MD-2) on immune cells. LPS aggregates 
on Gram-negative bacterial outer membranes are bound by lipopolysaccharide 
binding protein (LBP), which catalyzes their extraction and binding to CD14 
(Yu et al., 1997). CD14 delivers LPS to TLR4-MD2 complexes. The structural 
interaction between LPS, TLR4, and MD2 has been determined at a 3.1 Å 
resolution (Park et al., 2009). Binding of LPS to TLR4-MD2 leads to 
heterodimerization with another TLR4-MD2-LPS complex, in a symmetrical 
fashion (Park et al., 2009).  
 
TLR4 triggers both myeloid differentiation primary response 88 (MyD88)-
dependent and TIR domain-containing adaptor inducing IFN-β (TRIF)-
dependent signaling cascades. MyD88 is bridged to TLR4. It interacts with the 
serine/threonine kinase IL-1R-associated kinase (IRAK)-4, which activates 
IRAK-1 and IRAK-2. These IRAKs dissociate from MyD88 and bind TNFR-
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associated factor 6 (TRAF6), which acts as an E3 ubiquitin protein ligase. 
Together with an E2 ligase, TRAF6 forms a polyubiquitin chain that activates a 
complex of TGFβ-activated kinase 1 (TAK1) and TAK1-binding proteins 
(TABs) that phosphorylates IKK-β. This leads the IKK complex to 
phosphorylate the NF-κB inhibitor IκB, causing its degradation, releasing NF-
κB to translocate to the nucleus and activate expression of pro-inflammatory 
cytokine genes. Simultaneously, TAK1 activates MAP kinase cascades 
leading to the activation of the transcription factor AP-1, which also induces 
cytokine genes (Takeuchi and Akira, 2010) (Figure 3.1).  
LPS also induces translocation of TLR4 to the endosome together with the 
TRIF-related adaptor molecule (TRAM). This triggers TRIF-dependent 
signaling. Downstream of TRIF, TRAF6 and receptor-interacting protein (RIP1) 
activate NF-kB, leading to proinflammatory cytokine expression, whereas 
TRAF3 induces TANK-binding kinase 1 (TBK1) and IKK-i-mediated 
phosphorylation of interferon regulatory factor 3 (IRF3). Phosphorylated IRF3 
translocates into the nucleus, activating the expression of type I IFN genes 
(Takeuchi and Akira, 2010) (Figure 3.1). 
 
TLR signaling leads to the expression of proinflammatory cytokines such as 
IL-1β, TNFα, and IL-6. These cytokines orchestrate the immune response by 
regulating inflammatory cell survival, vascular permeability, and leukocyte 
recruitment (Takeuchi and Akira, 2010). 
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 Figure 3.1. LPS signaling via TLR4. LPS is recognized by TLR4/MD2 heterodimer. This recruits MyD88 to the receptor and a complex of IRAKs and TRAF6 is formed. TRAF6 catalyzes the formation of a polyubiquitin chain on TAK1/ TABs complex, activating it, and resulting in the phosphorylation and activation of an IKK complex. This phosphorylated IκB, leading to its degradation and the release of NF-κB to the nucleus, where it drives cytokine expression. TAK1 also phosphorylates MAPK, leading to AP-1 activation and cytokine expression. LPS causes translocation of TLR4 to the endosome, together with TRAM. This activates TRIF signaling, leading to NF-κB and IRF activation, resulting in cytokine and IFN expression. (Modified from Takeuchi 
and Akira, 2010). 
 
Figure 3.1
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3-1.3. Neutrophils and their proteases in inflammation 
Neutrophils account for about 70% of circulating immune cells, and as 
components of the innate immune system, they are the primary responders to 
infection. In order to accomplish that role, neutrophils express TLRs to detect 
pathogens and tailor the response to the pathogen detected. In addition to 
responding to pathogens, neutrophils have the ability to detect and respond to 
DAMPs, which can be released due to tissue damage and inflammation, 
further fueling the inflammatory response. Neutrophils express most TLRs, 
except two of the intracellular ones, TLR3 and TLR7 (Prince et al., 2011). 
 
Neutrophils are short-lived cells, and this functions as an anti-inflammatory 
mechanism in healthy tissues. Under normal conditions, circulating neutrophils 
have a half-life of around 7 hours. However, in response to a pathogenic 
insult, neutrophils recruited to the site of infection can survive up to 4 days 
(Doerschuk, 2001). For instance, LPS has been shown to act as a mediator of 
neutrophil survival (Hachiya et al., 1995). LPS in vitro enhanced the short term 
survival of neutrophils by signaling via TLR4 and both signaling arms 
downstream of TLR4: MyD88 and TRIF (Dick et al., 2009). Longer term 
enhancement of neutrophil survival in response to LPS is suggested to be 
dependent upon monocytes (Sabroe et al., 2002). 
 
1- Neutrophil granules 
Neutrophils carry four types of granules: azurophilic (also called primary), 
specific (secondary), gelatinase (tertiary), and secretory granules. The 
granules form sequentially during neutrophil differentiation in the bone marrow, 
with azurophilic granules forming early during the promyelocyte stage, 
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followed by specific, gelatinase, and finally secretory granules in later stages. 
Proteins synthesized at same stage during neutrophil differentiation are sorted 
into the same granules (Gullberg et al., 1997; Pham, 2006). The granules are 
also classified based on their ability to be exocytosed after neutrophil 
activation. By decreasing order of degranulation, the secretory granules are 
the most highly exocytosed, followed by gelatinase granules, specific 
granules, and finally the azurophilic granules (Pham, 2006). Azurophilic 
granules undergo limited exocytosis, and their activity is mostly intracellular, 
where they degrade pathogens in the phagolysosome (Korkmaz et al., 2008; 
Pham, 2006). Azurophilic granules carry high levels of myeloperoxidase 
(MPO), defensins, as well as the serine proteases neutrophil elastase (NE), 
cathepsin G (CG), and proteinase 3. The level of serine protease mRNAs is 
the highest during the promyelocytic stage of neutrophil differentiation in the 
bone marrow, and is later downregulated (Garwicz et al., 2005; Gullberg et al., 
1997), explaining why serine proteases are only found in early-forming 
azurophilic granules and excluded from later-forming granules. 
 
2- Neutrophil serine proteases 
Neutrophil serine proteases are 30-35 kDa enzymes, with an active site 
characterized by a serine residue. They contain a conserved catalytic triad 
composed of histidine, aspartic acid, and serine residues, which are spatially 
separated in the primary sequence but are brought together in the tertiary 
structures (Korkmaz et al., 2008; Pham, 2006). 
Neutrophil serine proteases are synthesized as inactive zymogens and require 
two cleavage steps at the amino-terminal to become active. First the signal 
peptide is cleaved, followed by cleavage of a dipeptide sequence by cathepsin 
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C before or during transport to granules (Adkison et al., 2002). C-terminal 
processing has been shown to be important for the localization of NE to 
granules (Horwitz et al., 2004), but this remains unclear for CG and  
proteinase 3. 
 
Released serine proteases are active in the neutral extracellular milieu. They 
can degrade ECM proteins and have overlapping substrates, like elastin, 
fibronectin, laminin, collagen, and proteoglycans (Korkmaz et al., 2008; Pham, 
2006). Neutrophil serine proteases play a role in ECM remodeling. Purified 
neutrophil elastase can cleave soluble type I collagen, as well as type I 
collagen fibrils (Kafienah et al., 1998; Zhu et al., 2001) and can increase 
fibroblast-mediated contraction of type I collagen, leading to ECM 
rearrangement (Sköld et al., 1999). Moreover, increased cathepsin G was 
shown to correlate with increased expression of type I and type III collagen in 
stenotic valves (Helske et al., 2006). 
Serine proteases are inhibited by serpins (serine protease inhibitors) found in 
the ECM. For instance, α1-antitrypsin (also called α1-protease inhibitor (α1-PI) 
inhibits the activity of neutrophil elastase, cathepsin G, and proteinase 3 
(Korkmaz et al., 2010). Some studies suggest that neutrophil serine proteases, 
once released extracellularly, bind to the plasma membrane of neutrophils, 
where they are active and simultaneously protected from the inhibitory effect 
of serpins (Owen and Campbell, 1999; Owen et al., 1995). However, the 
nature of this binding is still debated. 
 
The serine proteases also play a role in regulating inflammation by modulating 
various chemokines. Proteinase 3 can truncate the N-terminal of CXC-
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chemokine ligand 8 (CXCL8; also known as IL-8) (Padrines et al., 1994), and 
CG can truncate that of CXCL5 (Nufer et al., 1999), increasing their neutrophil 
chemotactic activity. CG also N-terminally truncates CC-chemokine ligand 15 
(CCL15) increasing its monocyte chemotactic activity (Berahovich et al., 
2005). Interestingly, NE can activate TLR4 through an unknown mechanism, 
leading to the expression of CXCL8 (Devaney et al., 2003). 
 
3- Neutrophils in lung inflammation 
Neutrophils cause lung damage by releasing proteases and reactive oxygen 
species in response to inflammatory signals. Neutrophil elastase is the major 
protease released by neutrophils in ALI. Elastase expression in neutrophils 
was found to be elevated in lungs of patients with ALI (Weiland et al., 1986), 
as well as in their bronchoalveolar lavage (BAL) (Suter et al., 1992). 
Collagenase (MMP8), stored in secondary granules of neutrophils can 
degrade collagen types I, II, and III. MMP8 activity is upregulated in lungs of 
patients with ALI (Christner et al., 1985). MMP2 and MMP9, the gelatinases 
stored in gelatinase granules of neutrophils, can degrade collagen type IV, 
which makes up basement membranes, as well as gelatin. MMP9 levels were 
found to be elevated in the BAL of patients in the early stages of ARDS 
(Delclaux et al., 1997). 
Finally, neutrophils produce reactive oxygen species, such as hydrogen 
peroxide and superoxides. Moreover, myeloperoxidase (MPO) stored in 
primary granules can catalyze the release of oxidants like hypochlorous acid 
(HOCl), which introduces pro-mutagenic DNA adducts (Güngör et al., 2010b). 
Patients with ALI have elevated levels of MPO in their BAL. 
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3-1.4. The role of inflammation in metastasis 
Recent reports demonstrate a positive association between lung inflammation 
and metastasis to the lungs. For instance, in a mouse model of autoimmune 
arthritis (AA), characterized by upregulated bone and lung inflammation, 
arthritic mice showed increased lung metastasis of mammary fat pad-injected 
4T1 cells, accompanied by a high degree of neutrophil infiltration in the lungs 
and high levels of MMP9, IL-17, and monocyte colony-stimulating factor (M-
CSF) in the BAL fluid. Interestingly, metastasis in AA mice was significantly 
suppressed by blocking inflammation, using anti- IL-17, either alone or with the 
Cox-2 inhibitor celecoxib (Das Roy et al., 2009). 
 
Another study tested the effect of surgery, and specifically endotoxin 
contamination during surgery, on metastasis. 4T1 mouse breast cancer cells 
were injected intravenously, followed by laparoscopic surgery (with air 
sufflation), laparatomy (midline incision), or LPS intraperitoneal injection. Both 
surgery and LPS challenge increased metastatic burden in lungs, 
accompanied by increased proliferation and decreased apoptosis in nodules 
(Pidgeon et al., 1999). Increased levels of LPS in circulation as a result of 
surgery or LPS challenge strongly correlated with increased circulating VEGF 
levels, indicating that LPS in the circulation enhances metastasis by increasing 
tumor proliferation, reducing tumor apoptosis, and promoting the production of 
VEGF (Pidgeon et al., 1999). Furthermore, LPS induced vascular permeability 
in mouse lungs and increased protein levels of inducible nitric oxide synthase 
(iNOS) and MMP2 in lung nodules, increasing extravasation of 4T1 tumor cells 
via a NOS-dependent mechanism (Harmey et al., 2002). 
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Moreover, bacterial- or LPS-induced lung inflammation through intranasal 
instillation enhanced lung metastasis of intravenously injected tumor cell lines, 
including B16-F10 melanoma, 4T1 breast cancer, RM-9 prostate cancer, and 
LLC lung cancer, as well as the metastasis of 4T1 orthotopic breast tumors to 
the lungs. This was mediated by increased extracellular ubiquitin levels in 
inflamed lungs, inducing migration via the CXCR4 receptor on the surface of 
tumor cells (Yan et al., 2013). Furthermore, E-selectin, an inflammation-
inducible endothelial cell adhesion molecule, mediated lung metastasis of 
intravenously injected 4T1 cells in response to systemic LPS, and this could 
be attributed to increased adhesion of tumor cells to lung endothelial cells 
(Jiang et al., 2014). E-selectin binds a molecule on leukocytes and tumor cells 
called sialyl Lewis x (sLex), which allows cells to be tethered to endothelial 
cells and to extravasate (Gout et al., 2008). E-selectin expression on 
endothelial cells is induced in response to pro-inflammatory mediators, like 
TNFα, IL-1β, VEGF, and LPS (Stannard et al., 2007; Vestweber and Blanks, 
1999). Moreover, intraperitoneal LPS treatment enhanced the lung metastatic 
growth of CT26 colon cancer and 4T1 breast cancer cell lines injected 
intravenously into mice, via a mechanism that involves LPS-driven induction of 
TNFα in host cells, leading to the paracrine activation of NF-κB signaling in 
tumor cells, upregulating proliferation and suppressing apoptosis (Luo et al., 
2004). 
In a different model of lung inflammation, lung epithelial activation of NF-kB by 
intratracheal instillation of an adenoviral vector expressing the active molecule 
of NF-κB, RelA (Ad-RelA), also known as p65, led to an initial influx of 
neutrophils, followed by recruitment and accumulation of macrophages, which 
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were the main effector cells promoting LLC tumor cell metastatic outgrowth in 
the lungs (Stathopoulos et al., 2008). 
 
Despite the above studies describing the link between inflammation and 
metastasis, the underlying mechanisms governing the contribution of the 
inflammatory distal microenvironment to enhanced metastasis are not fully 
understood. 
 
3-1.5. Tsp-1 as a mediator of pulmonary homeostasis 
Tsp-1 mRNA expression can be detected in the mouse lung at embryonic day 
14 and persists to embryonic day 18 (Iruela-Arispe et al., 1993). It is 
expressed in the bronchi by columnar epithelial cells, and the protein localizes 
to the basement membrane of the nascent bronchi in the mouse embryo 
(O’Shea and Dixit, 1988). Tsp-1 protein can also be detected in the basement 
membrane in the adult lungs (O’Shea and Dixit, 1988; Wight et al., 1985). 
In Tsp-1-deficient mice, signs of lung inflammation are visible starting 4 weeks 
of age, and consist of neutrophil and macrophage infiltration, followed by 
collagen and elastin deposition, and airway epithelial thickening due to 
epithelial hyperplasia (Lawler et al., 1998). Furthermore, recruited 
macrophages become laden with the iron storage complex hemosiderin, an 
indicator of alveolar hemorrhage, subsequent to tissue damage (Lawler et al., 
1998). 
These studies suggest that Tsp-1 is a mediator of lung homeostasis, at least 
partly through the regulation of the inflammatory response. Tsp-1 deficiency 
results in longer inflammation and confers worse lung fibrosis in response to 
bleomycin treatment (Ezzie et al., 2011; Lamy et al., 2007). 
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Based on the extensive literature describing the intricate connection between 
inflammatory components, the premetastatic niche, and metastasis, we 
undertook a comprehensive mechanistic approach to determine the direct 
impact of pre-existing lung inflammation, caused by external insults, on 
metastasis progression. 
 
3-2. RESULTS  
3-2.1. Lung inflammation enhances metastatic outgrowth.  
To determine the contribution of the inflammatory microenvironment to the 
outgrowth of metastasis, we experimentally induced an inflammatory state in 
mouse lungs through intranasal instillation of LPS. We used LPS, as it is a 
well-known inducer of inflammation, previously used to study colon cancer and 
breast cancer metastasis to the lung (Jiang et al., 2014; Luo et al., 2004; Yan 
et al., 2013). Importantly, mechanisms of LPS-mediated inflammation are well 
described. Both systemic or intranasal administration of LPS has been 
reported to induce neutrophil influx to the lungs (Jiang et al., 2014; Luo et al., 
2004; Yan et al., 2013). Furthermore, the binding of LPS to TLR4 on immune 
cells leads to activation of NF-κB, promoting the expression of pro-
inflammatory cytokines, including IL-1β, TNFα, and IL-6 (Takeuchi and Akira, 
2010). In addition to acute lung injury (ALI), whose major causative factor is 
LPS (Brigham and Meyrick, 1986), other lung inflammatory conditions are 
marked with increased neutrophil influx and upregulation of the mentioned pro-
inflammatory cytokines, including severe asthma (Fahy, 2009), COPD (Chung, 
2001; Jeffery, 1998), and pneumonia (Craig et al., 2009; Yamamoto et al., 
2014). With respect to the route of LPS administration, intranasal delivery was 
used to generate lung-specific inflammation, since our goal was to determine 
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the impact of pulmonary inflammation on promoting metastasis to the lung. As 
expected, intranasal LPS administration resulted in recruitment of neutrophils, 
determined by myeloperoxidase staining, specifically to the lungs and not to 
other organs, including the liver and kidneys, indicating the absence of 
systemic inflammation (Figure 3.2a). Administration of luciferase-labeled 
Lewis lung carcinoma (LLC) cells that are metastatic to the lungs (Gao et al., 
2008; Kim et al., 2009) via tail vein resulted in significantly increased 
metastatic burden in the LPS-challenged lungs compared to controls (Figure 
3.2b). Similarly, the tail vein-injected B16-BL6 melanoma cell line that is 
metastatic to lungs (Nakamura et al., 2002) showed increased metastatic 
lesions following LPS challenge (Figure 3.2c), suggesting that the contribution 
of inflammation to metastasis is relevant across tumor types. Next, we 
determined if LPS-mediated inflammation in the lungs would enhance 
melanoma metastasis from the orthotopic site. To this end, B16-BL6 
melanoma cells were implanted subcutaneously in the flank and allowed to 
form primary tumors for three weeks. Mice were then challenged with LPS for 
a week, after which primary tumors were resected and metastasis was allowed 
to proceed for another three weeks. At the time of lung harvest, LPS-
challenged lungs showed enhanced metastasis from subcutaneous B16-BL6 
primary melanoma tumors (Figure 3.3a). These results suggest that 
inflammation in distant organs can accelerate the rate of metastasis of primary 
tumors.  
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Figure 3.2. LPS-driven lung inflammation enhances metastatic outgrowth 
of tail vein-injected tumor cell lines.  
(a) Representative IHC of myeloperoxidase (MPO) in lungs, livers, and 
kidneys of mice challenged intranasally with 12.5 µg of LPS or the equivalent 
volume of PBS (Ctrl). Insets show magnified areas of lung.   
(b) Top panel, Quantitation of pulmonary metastasis by bioluminescence 
imaging of mice challenged with PBS (Ctrl) or LPS, followed by tail-vein 
injection of 1x105 luciferase-labeled LLC cells, 3 days after last PBS/LPS 
dose. BLI estimates were obtained at day 15 following tail vein injections and 
are represented as means ± SEM (n= 5 mice/ group). *, p=0.048 (one-tailed 
Mann-Whitney U test). Bottom panel, Representative BLI showing increased 
metastatic burden in intranasal LPS-treated mice.  
(c) Top panel, Quantitation of B16-BL6 melanoma lung metastases in mice 
following intranasal administration of PBS (Ctrl), or LPS. Stereological 
measurements were obtained 18 days following tail vein injection of 2x105 
B16-BL6 cells. Data are plotted as the means ± SEM (n=10/ group). **, 
p=0.002 (one-tailed t test with Welch’s correction). Bottom panel, 
Representative H&E stains showing increased metastatic burden in LPS-
challenged mice. 
(Data in Figure 3.2 generated in collaboration with Dr. R. Catena. Panels a 
and b generated by R. Catena.)  
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Figure 3.3. LPS-driven lung inflammation enhances metastatic outgrowth 
of orthotopically implanted melanoma.  
(a) Left panel, Quantitation of metastasis in lungs of PBS- (Ctrl) or LPS-
challenged mice, 6 weeks post primary tumor inoculation. Data represented as 
mean ± SD. (n=3 Ctrl mice and 4 LPS mice. 5-8 sections per lung were 
analyzed stereologically. p= 0.025, one-tailed Mann-Whitney U test). Right 
panel, Representative H&E staining of PBS- (Ctrl) and LPS-challenged lungs, 
6 weeks post primary tumor inoculation.  
(b) Top panel, Immunofluorescence-based quantitation of neutrophil 
recruitment to lungs, 3 days after the last intranasal administration of PBS 
(Ctrl) or LPS. Data represented as mean ± SEM. (n= 3 mice per group, 2 
sections per lung, 8 fields per section). p<0.0001, one-tailed Mann-Whitney U. 
Bottom panel, Representative immunofluorescence micrographs of neutrophils 
in lungs. Ly6G in green, DAPI in blue. Scale bar = 20 µm.  
(c) Immunofluorescence-based quantitation of CD45+ cell recruitment to lungs 
of non-tumor-bearing (Ctrl) mice, or tumor-bearing PBS-treated (Tum-Ctrl) or 
LPS-treated (Tum-LPS). Data represented as mean ± SEM. (n= 3 mice per 
group, 2 sections per lung, 9 fields per section). p<0.0001, one-tailed t test for 
comparisons between Ctrl and Tum-Ctrl, as well as Ctrl and Tum-LPS.  
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3-2.2. Inflamed lungs show enhanced neutrophil recruitment that promotes 
metastatic outgrowth, and upregulation of cytokines.  
To further understand this phenomenon of enhanced metastasis, we 
evaluated the cellular composition of inflammatory cells in tumor-free LPS-
challenged lungs. Flow cytometry analysis revealed significantly increased 
recruitment (>7-folds) of bone marrow (BM)-derived CD45+ CD11b+ Ly6G+ 
neutrophils in LPS-challenged lungs compared to control lungs (Figure 3.4a). 
Increased recruitment of CD11b+ Ly6G+ cells in LPS-challenged lungs was 
corroborated by immunofluorescence staining (Figure 3.4b). Interestingly, 
increased recruitment of Ly6G+ neutrophils was also observed in the lungs of 
primary melanoma-bearing mice, after LPS challenge, while total CD45+ cells 
recruited remained unchanged (Figure 3.3b, c).  
On the molecular level, elevated expression of inflammatory mediators, 
including interleukin-1 beta (IL-1β), tumor necrosis factor alpha (TNFα), 
interleukin-6 (IL-6), and Cox-2, was detected in the LPS-challenged lungs and 
in Ly6G+ cells sorted from these lungs (Figure 3.4c, d). These results 
suggested that neutrophil–mediated inflammation in the lungs contributes to 
the enhanced metastasis. To evaluate this hypothesis, neutrophils were 
depleted by using anti-Ly6G neutralizing antibody (Daley et al., 2008), and 
metastasis of tail vein-injected LLC cells was monitored following LPS 
challenge. The efficiency of neutrophil depletion was assayed in peripheral 
blood, where the circulating neutrophil population was seen to be significantly 
depleted (Figure 3.5b). Notably, neutrophil depletion resulted in diminished 
metastatic burden (Figure 3.5a), which further confirmed the contribution of 
neutrophils to metastasis. 
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Figure 3.4. LPS challenge upregulates neutrophil recruitment and pro-
inflammatory mediator expression in the lungs.  
(a) Flow cytometry-based quantitation of bone marrow-derived cells in lungs of 
PBS- (Ctrl) or LPS-challenged lungs 3 days after the last treatment. Fold 
increase depicted as percentage of each cell population in LPS-treated lungs 
compared to that in control lungs. Red dotted line represents a fold increase of 
1. (n=3 mice/ group). CD45: hematopoietic cells; CD11b: myeloid cells; CD3: 
T cells; CD25: lymphocytes; B220: B cells; VEGFR1: hematopoietic progenitor 
cells; F4/80: macrophages; Gr1: myeloid cells; Ly6G: granulocytes 
(neutrophils); Ly6C: monocytes; c-Kit: hematopoietic progenitor cells; CD49b: 
natural killer (NK) cells; CD11c: dendritic cells.  
(b) Representative immunofluorescence staining of CD11b+ and Ly6G+ cells in 
lungs from PBS- (Ctrl) and LPS-treated mice. Magnified panel shows 
colocalization CD11b and Ly6G markers (white arrows, n=5 mice, 4 sections 
per mouse, 7-10 fields per section).  
(c) Representative quantitative RT-PCR depicting the normalized fold 
expression of the pro-inflammatory cytokines IL-1β, IL-6, and TNFα in LPS-
challenged lungs compared to control PBS-challenged lungs.  
(d) Representative quantitative RT-PCR depicting the normalized fold 
expression of the pro-inflammatory cytokines IL-1β, IL-6, TNFα, and Cox-2 in 
Ly6G+ cells sorted from LPS-challenged lungs compared to control PBS-
challenged lungs. Control expression levels are set to 1. Numbers signify fold 
expression relative to controls. (n=3 mice per group. Experiment was repeated 
3 times with comparable results). 
(Data in Figure 3.4 generated in collaboration with Dr. R. Catena. Panels a 
and b generated by R. Catena.)  
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Figure 3.5. Depletion of Ly6G+ neutrophils reduces metastatic outgrowth of tail vein-injected LLCs following LPS challenge.  (a) Top panel, Quantification of pulmonary metastases using BLI at day 21 in mice administered with IgG isotype antibody or anti-Ly6G neutralizing antibody, followed by tail vein injection of luciferase-labeled LLC cells (n=5 per group). Bottom panel, Representative BLI images.  
(b) Flow cytometry-based quantification of Ly6G+ cells in the peripheral blood 
of isotype-treated and anti-Ly6G-treated mice (n=3 per group). p< 0.001 (one-
tailed Mann-Whitney U test).  
(Data in Figure 3.5 generated in collaboration with Dr. R. Catena. Panels a 
and b generated by R. Catena.)  
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3-2.3. Inflamed lungs exhibit loss of Tsp-1 and upregulation of neutrophil 
serine protease activity. 
To elucidate the mechanisms by which neutrophils in the inflamed lungs 
promote metastasis, we focused on thrombospondin-1 (Tsp-1), a secreted 
protein, present transiently in the extracellular matrix, which is critical for 
normal lung homeostasis and inflammation (Ezzie et al., 2011; Lamy et al., 
2007; Lawler et al., 1998; Lopez-Dee et al., 2011). More importantly, we had 
previously demonstrated that myeloid-derived Tsp-1 in lungs is required for 
metastasis suppression (Catena et al., 2013). Strikingly, Western blot analysis 
showed almost complete loss of Tsp-1 protein in LPS-inflamed lungs 
compared to control lungs (Figure 3.6a). This observation is novel, as 
previous studies have described other mechanisms of Tsp-1 cleavage, leading 
to the generation of cleavage products with their own anti-angiogenic activities 
(Lawler, 1986; Lee et al., 2006b; Taraboletti et al., 1997) (see discussion). 
Functionally, Tsp-1 is a potent inhibitor of tumor angiogenesis and growth 
(Good et al., 1990; Lawler, 1986) suggesting that decreased Tsp-1 protein 
levels in the inflamed lungs may be the cause of enhanced metastasis. 
However, given that Ly6G+ neutrophils are a main source of Tsp-1 in the lungs 
(Figure 2.4c) (Catena et al., 2013), it was surprising to observe the dramatic 
loss of Tsp-1 protein in inflamed lungs, despite the increased influx of Ly6G+ 
cells. When we analyzed Ly6G+ neutrophils more closely, we discovered that 
the loss of Tsp-1 protein was not due to a reduction in Tsp-1 mRNA levels 
within Ly6G+ neutrophils (Figure 3.6b), suggesting post-translational 
regulation of Tsp-1 protein. 
Specifically, we hypothesized that Tsp-1 in inflamed lungs may have been 
subjected to proteolytic degradation. In this context, Ly6G+ neutrophils carry a 
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Figure 3.6. LPS challenge is associated with loss of Tsp-1 protein and increased neutrophil protease activity in lungs.  (a) Western blot analysis of Tsp-1 levels in the lungs of WT mice challenged with PBS (Control, n=3 mice) or LPS (n=4 mice). β-actin is a loading control. Experiment was reproduced 3 times with comparable results.  (b) Quantitative RT-PCR analysis of Tsp-1 in flow cytometry-sorted Ly6G+ cells from the lungs of PBS- (Ctrl) or LPS-challenged mice. Samples were normalized based on equal Ly6G+ cell numbers, and normalized to GAPDH mRNA. Data are plotted as the means ± SEM (n=3 mice per group, in duplicates).  PBS group used as control for relative expression (2–ΔΔCt).  (c) Flow cytometry analysis of CD63 median fluorescence intensity in the CD11b+ Ly6G+ population in lungs of PBS- (Ctrl) and LPS-challenged mice. Data are plotted as the means ± SEM (n=4/ group). *, p=0.029 (one-tailed Mann-Whitney U test). Experiment was reproduced twice with comparable results.  
(d) Neutrophil elastase activity (Left panel) and cathepsin G activity (Right 
panel) in lungs of PBS-treated (Ctrl) and LPS-treated mice. Activity presented 
as relative fluorescence unit per minute (RFU/min) and plotted as the means ± 
SEM (n=4 per group). *, p= 0.018 and 0.029 for elastase activity and cathepsin 
G activity, respectively (one-tailed Mann-Whitney U test).  
(Data in Figure 3.6 generated in collaboration with Dr. R. Catena. Panel d 
generated by R. Catena.)  
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variety of granules which are stores for specific proteases, among which two 
serine proteases, neutrophil elastase (NE) and cathepsin G (CG), have been 
shown to possess high binding affinities for Tsp-1 (Hogg et al., 1994). Given 
that NE and CG are stored in specialized azurophilic granules, and 
inflammation is a major trigger of neutrophil degranulation (Faurschou and 
Borregaard, 2003; Korkmaz et al., 2010), we speculated that degranulating 
neutrophils in the inflamed lungs, by virtue of secreting NE and CG, may have 
resulted in Tsp-1 proteolysis. Indeed, increased neutrophil degranulation was 
detected in LPS-challenged inflamed lungs compared to controls (Figure 
3.6c), as determined by increased cell surface presentation of the azurophilic 
granule membrane molecule, CD63, on Ly6G+ neutrophils (Kuijpers et al., 
1991; Simard et al., 2010). CD63 is exclusively expressed on the membrane 
of azurophilic granules of resting neutrophils, and is a marker of azurophilic 
granule fusion with the neutrophil plasma membrane during degranulation 
(Kuijpers et al., 1991). Increased neutrophil degranulation was associated with 
enhanced activity of both NE and CG proteases in LPS-inflamed lungs 
compared to controls (Figure 3.6d).   
 
3-2.4. A genetic model of inflammation captures key events observed in LPS-
driven inflammation. 
To evaluate whether the observations derived from the LPS model of 
inflammation are generalizable to other models of inflammation, we used a 
genetic model of inflammation. In the CCSP-rtTA;tetO-IL-1β bitransgenic 
mouse model of inflammation, the potent inflammatory cytokine IL-1β is 
conditionally expressed in the lung epithelium, under the Clara cell secretory 
protein (CCSP) promoter, when mice are administered with doxycycline 
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(Lappalainen et al., 2005).  In this model, induction of IL-1β causes a 
significant increase in neutrophils in the BAL of mice, and causes pulmonary 
inflammation in the adult murine lung (Lappalainen et al., 2005). Consistent 
with the LPS model, lungs from IL-1β bitransgenic mice fed with doxycycline 
showed significantly increased recruitment of Ly6G+ neutrophils, and elevated 
levels of pro-inflammatory mediators, including IL-1β, TNFα, and Cox-2, 
compared to their littermates (Figure 3.7a, b). Notably, there was a significant 
increase in NE and CG activity, associated with degradation of Tsp-1 protein 
in the lungs (Figure 3.7c, d). These results demonstrate that the observed 
loss of Tsp-1 protein is an effect of lung inflammation rather than an artifact of 
LPS challenge. Taken together, these data suggest that NE and CG are likely 
candidates causing proteolytic degradation of Tsp-1.   
 
3-2.5. NE and CG degrade Tsp-1 in vitro. 
To demonstrate that NE and CG actually possess Tsp-1 proteolysis activity, 
we performed in vitro proteolysis assays, in which recombinant Tsp-1 protein 
was incubated with either recombinant NE or CG proteins for different time 
intervals, followed by a Western blot to detect Tsp-1 protein levels. Both NE 
and CG resulted in the degradation of Tsp-1, and this degradation was 
blocked in the presence of protease-specific inhibitors (Figure 3.8a, b). We 
also tested Sivelestat (ONO-5046), a pharmacological inhibitor of NE (IC50 = 
44 nM, Ki = 0.2 μM), that has been shown to prevent acute lung injury in 
animal models (Hagio et al., 2004, 2005) and is currently in Phase III clinical 
trials for ALI associated with systemic inflammatory response syndrome  
(SIRS) (Iwata et al., 2010). As expected, Sivelestat inhibited NE-mediated 
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Figure 3.7. Ectopic expression of IL-1β in lungs promotes neutrophil 
recruitment and Tsp-1 degradation.  
(a) Left panel, Representative scatter plots depicting flow cytometry analysis of 
Ly6G+ cells in lungs of CCSP-rtTA; tetO-IL-1β  or age-matched control 
littermates (WT or CCSP-rtTA single transgenic) fed with doxycycline for 10 
days (n=5 controls and 7 CCSP-rtTA; tetO-IL-1β). Right panel, Flow 
cytometry-based quantification of Ly6G+ cells in lungs of CCSP-rtTA; tetO-IL-
1β mice or controls fed with doxycycline for 10 days. Data are plotted as 
means ± SEM (n=5 controls and 7 CCSP-rtTA; tetO-IL-1β).   *, p= 0.006 (one-
tailed t test).  
(b) Representative quantitative RT-PCR depicting the normalized expression 
of the pro-inflammatory mediators IL-1β, TNFα, and Cox-2 in lungs of CCSP-
rtTA; tetO-IL-1β mice and controls fed with doxycycline for 10 days. (n=5 
controls and 7 CCSP-rtTA; tetO-IL-1β, in duplicates). Means ± SEM are 
shown. p=0.005, p=0.025, and p=0.01 for IL-1β, TNFα, and Cox-2, 
respectively (one-tailed t test for IL-1β and TNFα; one-tailed Mann-Whitney U 
test for Cox-2).  
(c) Neutrophil elastase (Left panel) and cathepsin G (Right panel) activity in 
lungs of CCSP-rtTA; tetO-IL-1β mice and controls fed with doxycycline for 10 
days. (n=5 controls and 7 CCSP-rtTA; tetO-IL-1β). Activity represented as 
relative fluorescence unit per minute (RFU/min). Means ± SEM are shown. *, 
p= 0.038 for elastase activity (one-tailed t test), and p= 0.013 for cathepsin G 
activity (one-tailed t test).  
(d) Western blot analysis of Tsp-1 in pooled lungs of bitransgenic mice or 
littermates fed with doxycycline for 10 days. (n=5 controls and 7 CCSP-rtTA; 
tetO-IL-1β). β-actin is used as loading control. 
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Figure 3.8. Neutrophil-derived proteases elastase (NE) and cathepsin G 
(CG) degrade Tsp-1.  
(a, b) In vitro degradation assays of recombinant Tsp-1 with recombinant NE 
and CG proteases, alone, or in combination with the specific inhibitors of NE 
(N-(Methoxysuccinyl)-Ala-Ala-Pro-Val-chloromethyl ketone) or CG (Z-Gly-Leu-
Phe-CMK), and Sivelestat. Recombinant protein incubations were followed by 
Western blot analysis for Tsp-1 levels. Experiments repeated 3 times with 
similar results.  
(c) Representative flow cytometry analysis of degranulation marker CD63, in 
CD11b+ Ly6G+ cells cultured in vitro with 0.01% DMSO (Ctrl, solid grey 
histogram), 20 nM TPA (TPA, empty blue histogram), or 20 nM TPA + 0.05 
µg/µl Sivelestat (TPA + Siv, solid red histogram).  
(d) Representative protease activity assays for elastase (Left panel) and 
cathepsin G (Right panel) in conditioned media of Ly6G+ cells cultured in vitro 
with 20 nM TPA or 20 nM TPA + 0.05 µg/µl Sivelestat. Activities represented 
as relative fluorescence units (RFU) as a function of time. 
(e) Western blot analysis of Tsp-1 in conditioned media of Ly6G+ cells cultured 
in the presence of TPA or TPA + Siv at time 0, 30, 60, and 120 min. Ponceau 
S staining shows equal protein loading. 
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Tsp-1 proteolysis (Figure 3.8a). Strikingly, Sivelestat also reduced CG-
mediated Tsp-1 proteolysis (Figure 3.8b), thereby exhibiting dual protease 
inhibitor activity. This is a novel finding, and it could be explained by the fact 
that NE and CG show high structural similarity and display a root mean square 
deviation (RMSD) of 1.03 Å when 201 of their α-carbons are superimposed 
(Averhoff et al., 2008). Furthermore, NE and CG share the same catalytic triad 
composed of histidine, aspartate, and serine residues at identical positions 
(His57, Asp102 and Ser195) in both enzymes (Korkmaz et al., 2008).  
To expand upon the role of neutrophils in Tsp-1 proteolysis through 
degranulation of proteases, we isolated neutrophils and induced their 
degranulation using the phorbol ester tetradecanoyl phorbol acetate (TPA), 
widely used in the literature to study neutrophil activity (Jones et al., 2002; 
Manara et al., 1991; Xu and Håkansson, 2002). TPA-induced neutrophil 
degranulation was confirmed by the membrane presentation of CD63 
quantified by flow cytometry (Figure 3.8c). Conditioned media (CM) from TPA-
treated neutrophils showed an increase in NE and CG protease activity 
(Figure 3.8d). TPA-treated neutrophil CM also exhibited proteolysis of 
endogenous neutrophil-secreted Tsp-1, as determined by time course analysis 
(Figure 3.8e). Notably, Sivelestat concurrently blocked NE and CG protease 
activity in the CM and protected Tsp-1 from proteolysis (Figure 3.8d, e), 
without inhibiting TPA-mediated neutrophil degranulation (Figure 3.8c). These 
results demonstrate that both NE and CG can degrade Tsp-1. Furthermore, 
Sivelestat acts as a dual protease inhibitor, protecting Tsp-1 from degradation.  
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3-2.6. NE and CG degrade Tsp-1 in vivo  
Our in vitro data suggest that Tsp-1 degradation observed in inflamed lungs 
may be mediated by the activity of the degranulated neutrophil proteases NE 
and CG. However, to address the causal relationship between increased 
protease activity and Tsp-1 degradation, we made use of NE and CG double 
knockout (NE-/- CG-/-) mice, which we generated in the lab by breeding NE-/- 
mice to CG-/- mice (Figure 3.9a). We determined that Ly6G+ neutrophils 
harvested from the BM of NE-/- CG-/- mice showed similar degrees of 
degranulation in vitro as neutrophils harvested from the BM of wild type mice 
following treatment with TPA (Figure 3.9b). As expected, neutrophils 
harvested from NE-/- CG-/- mice lacked significant NE and CG activity (Figure 
3.9c), and more importantly, failed to induce Tsp-1 degradation, compared to 
wild type controls in vitro (Figure 3.9d).  
Next, we challenged these mice with LPS to induce lung inflammation. As 
expected, lungs of wild type control mice showed Tsp-1 degradation; however, 
lungs of NE-/- CG-/- mice showed protection of Tsp-1 from proteolysis (Figure 
3.10a). This was not due to degranulation defects, since comparable 
degranulation of neutrophils was observed in the lungs in both groups, 
assayed by flow cytometry of CD63 cell surface expression in Ly6G+ 
neutrophils (Figure 3.10b).  
Taken together, these data suggest that the neutrophil proteases NE and CG 
mediate Tsp-1 proteolysis both in vitro and in vivo.  Moreover, in contrast to 
previous studies, where specific Tsp-1 cleavage was shown to contribute to 
Tsp-1 function (Lawler, 1986; Lee et al., 2006b; Taraboletti et al., 1997), in our 
study, none of these cleavage products appear in the inflamed lungs of mice  
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Figure 3.9. NE-/- CG-/- neutrophils don’t degrade Tsp-1.  
(a) Top panel, Genotyping PCR of NE-/- CG-/- mice compared to CG+/- (het) 
and CG-/- mice, using CG primers. WT band is 475 bp and mutant band is 330 
bp. Bottom panel, Genotyping PCR of NE-/- CG-/- mice compared to WT and 
NE-/- mice, using NE primers. WT band is 230 bp and mutant band is 310 bp. 
(b) Representative flow cytometry analysis of the degranulation marker CD63 
in Ly6G+ cells isolated from WT (solid purple histogram) or NE-/- CG-/- (empty 
green histogram) mice and cultured in vitro with 20 nM TPA.  
(c) Neutrophil elastase activity (Left panel) and cathepsin G activity (Right 
panel) in conditioned media of Ly6G+ cells isolated from WT and NE-/- CG-/- 
mouse bone marrows and cultured with 20 nM TPA for 30 min. Data are 
plotted as the means ± SEM (n=3/ group). ***, p< 0.001 for NE activity and for 
CG activity (Analysis of Covariance, ANCOVA, comparing activity curves).  
(d) Representative Western blot analysis of Tsp-1 in conditioned media from 
Ly6G+ cells isolated from WT and NE-/- CG-/- mouse bone marrows and 
cultured with 20nM TPA for t= 0, 2 hours, or 4 hours. Ponceau S stain is used 
as loading control. Repeated twice with similar results. 
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Figure 3.10. Neutrophil-derived NE and CG degrade Tsp-1 in vivo.  
(a) Western blot analysis of Tsp-1 protein in lungs of WT and NE-/- CG-/- mice (n=4 per group) treated with LPS. Protein samples are pooled from 4 mice per 
group.  β-actin serves as a loading control.  (b) Flow cytometry analysis of the median fluorescence intensity of the degranulation marker CD63 in CD11b+ Ly6G+ cells in lungs of WT and NE-/- CG-/- mice treated with LPS. Data are plotted as means ± SEM (n= 4 lungs per group).  ns: not significant (two-tailed Mann-Whitney U test).  (c) Left panel, Western blot analysis of Tsp-1 in lungs from mice challenged intranasally with PBS or LPS. Full-length Tsp-1 runs as double band between 110 kDa and 170 kDa. Right panel, Western blot analysis of Tsp-1 in lungs from WT and Tsp-1-/- mice challenged intranasally with PBS. Protein from Tsp-1-/- mice is used to determine non-specific bands, which appear as a result of using a mouse-derived Tsp-1 antibody on mouse lungs, and having to use an anti-mouse secondary antibody for detection. Of note: The Tsp-1 antibody clone we use is the Ab-11 clone, which has the ability to recognize the N-terminal heparin-binding domain, the calcium-binding domain, and the collagen type V-binding domain of Tsp-1.  
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(Figure 3.10c), suggesting a novel mechanism of Tsp-1 regulation by 
combined proteolytic activity of NE and CG.  
 
3-2.7.NE- and CG-mediated Tsp-1 degradation is required for inflammation-
enhanced metastasis. 
To determine the impact of inflammation-driven protease activity on 
metastasis and the contribution of NE/CG-Tsp-1 axis in promoting metastasis 
in LPS-inflamed lungs, we generated NE and CG deficiency in the BM.  
Initially, we generated single deletions in NE or CG separately in the BM by 
transplanting NE-/- BM or CG-/- BM into irradiated syngeneic WT mice, to 
generate cohorts of NE-/- BMT or CG-/- BMT mice. As controls, BM from WT 
mice was transplanted into irradiated WT mice to generate a cohort of WT 
BMT mice. NE or CG deficiency in the BM did not affect hematopoietic cell 
composition (Figure 3.11a). More importantly, deficiency in only one of the 
proteases in the BM only partially impaired metastatic outgrowth of tail vein-
injected LLC cells after LPS challenge in NE-/- BMT and CG-/- BMT mice 
compared to WT BMT mice, as determined by BLI analysis (Figure 3.11b). 
This suggests that the activity of both proteases could be necessary to 
enhance metastasis. To evaluate this hypothesis, we generated NE-/- CG-/- 
double knockout mice, harvested their BM cells, and transplanted them into 
irradiated syngeneic wild type mice to generate a cohort of NE-/- CG-/- BMT 
mice. Importantly, combined NE and CG deficiency in BM cells in NE-/- CG-/- 
BMT mice did not perturb the mobilization of Ly6G+ neutrophils in the 
peripheral blood, their recruitment to the lung microenvironment, or their 
degranulation in lungs after LPS treatment (Figure 3.12a-c). Furthermore, 
deficiency of NE and CG in the BM did not disrupt the composition of  
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Figure 3.11. Single NE-/- or CG-/- does not significantly impair LPS-mediated metastasis enhancement.  (a) Flow cytometry-based quantitation of hematopoietic cell subsets in blood of WT BMT and NE-/- BMT mice (Left panel) or WT BMT and CG-/- BMT mice (Right panel).  
(b) Analysis of bioluminescence imaging showing luciferase-labeled LLC cell 
outgrowth in lungs of WT BMT and NE-/- BMT mice (Left panel, n= 8 
mice/group; p= 0.4796, one-tailed Mann-Whitney U test) or CG-/- BMT mice 
(Right panel, n= 8 mice/group).  
(Data in Figure 3.11 generated in collaboration with Dr. R. Catena. Panels a 
and b generated by R. Catena.)  
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Figure 3.12. NE and CG deficiency in the bone marrow compartment 
does not impact neutrophil recruitment to lungs, their degranulation, or 
hematopoietic reconstitution.  
(a) Flow cytometry-based quantitation of CD11b+ Ly6G+ cells in blood of PBS-
treated WT BMT, and LPS-treated WT BMT or NE-/- CG-/- BMT mice. (n= 4 
mice per group, p= 0.044 between WT BMT and WT BMT + LPS, and p= 
0.016 between WT BMT and NE-/- CG-/- BMT + LPS. Two-tailed t test).  
(b) Flow cytometry-based quantitation of CD45+ hematopoietic cells and 
Ly6G+  neutrophils recruited to lungs of WT BMT and NE-/- CG-/- BMT mice 
treated with LPS (n= 4 mice per group,  Differences are not statistically 
significant, as determined by two-tailed Mann-Whitney U test). Lungs were 
collected 3 days after LPS treatment.  
(c) Flow cytometry-based quantitation of CD63 mean fluorescence intensity 
(MFI) of Ly6G+ cells in lungs of WT BMT and NE-/- CG-/- BMT mice treated with 
LPS (n=4 per group,   
p= 0.305 as determined by two-tailed unpaired t test).  
(d) Flow cytometry-based quantitation of hematopoietic cell subsets in blood of 
WT BMT and NE-/- CG-/- BMT mice (p= 0.1 for CD45+ cells;  p= 0.4 for CD11b+ 
cells;  p=0.4 for Ly6G+ cells;  p= 0.475 for CD3+ cells and p= 0.628 for B220+ 
cells). Statistical analysis used is two-tailed Mann-Whitney U test. 
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hematopoietic cell subsets (Figure 3.12d). After having characterized these 
critical parameters in the NE-/- CG-/- BMT mice, we determined the impact of 
NE and CG deficiency in the lung microenvironment on metastasis, following 
inflammation. Strikingly, we observed impaired metastatic outgrowth of tail 
vein-injected LLC cells after LPS challenge in NE-/- CG-/- BMT mice compared 
to WT BMT mice, as determined by BLI and analysis of lungs by H&E (Figure 
3.13a). Western blot analysis of total lung lysates showed protection of Tsp-1 
from proteolysis in NE-/- CG-/- BMT mice compared to wild type controls 
(Figure 3.13b). Together, these results demonstrate that both proteases are 
needed to enhance metastasis in response to inflammation, and the neutrophil 
NE/CG-Tsp-1 axis is a major contributor to metastasis.   
 
3-2.8. Pharmacological blockade of NE and CG suppresses metastasis. 
To determine the clinical feasibility of blocking neutrophil proteases as a 
potential anti-metastasis strategy, we used a pharmacological approach to 
inhibit the activity of both proteases. Our finding that Sivelestat inhibits both 
NE and CG activities (Figure 3.8) allowed us to test its therapeutic efficacy in 
blocking metastasis in vivo. Treatment of tumor-bearing mice daily with 
Sivelestat dramatically blocked metastasis (Figure 3.14a, b). Sivelestat did 
not significantly impact the recruitment of neutrophils to the lungs or influence 
their degranulation potential (Figure 3.14c, d), suggesting that protease 
inhibition is the main cause of impaired metastasis. It is to be noted that the 
metastasis experiments with Sivelestat were performed in the absence of LPS 
challenge. Perhaps, neutrophils recruited by metastasis-initiating nodules were 
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Figure 3.13. Neutrophil-derived NE and CG enhance metastasis.  
(a) Top panel, Quantification of metastatic burden via bioluminescence imaging in 
WT BMT and NE-/- CG-/- BMT mice treated with LPS and tail vein-injected with LLC 
tumor cells. Signals were normalized to the readings obtained at day 4 for each 
individual animal. Data at each time point is plotted as means ± SEM (n= 8 mice per 
group). *, p= 0.038 at day 21 (one-tailed t test with Welch's correction). Bottom panel, 
Representative H&E stains of lungs collected at day 21 from WT and NE-/- CG-/- BMT 
mice treated with LPS (n= 8 mice per group).  
(b) Western blot analysis of Tsp-1 in lung samples from WT BMT and NE-/- CG-/- BMT 
mice treated with LPS. Samples are pooled from 3 mice per group. β-actin serves as 
a loading control. 
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Figure 3.14. Pharmacological inhibition of the proteases using Sivelestat 
suppresses metastasis.  
(a) Quantitation of metastatic burden via bioluminescence imaging in PBS-
treated (Ctrl) and Sivelestat-treated (Siv) WT mice tail vein-injected with 
luciferase-labeled LLC cells. Signals were normalized to the readings obtained 
at day 5 for each individual animal. (n=7 per group, p= 0.0224 at day 23 as 
determined by two-tailed t test with Welch's correction). Data are represented 
as mean ± SEM.  
(b) Quantitation of mean lung metastasis area in PBS-treated (Ctrl) and 
Sivelestat-treated (Siv) mice. (n= 6 per group, p= 0.043 as determined by one-
tailed t test). Data are represented as mean ± SEM.  
(c) Flow cytometry-based quantitation of CD11b+ Ly6G+ cells in the lungs of 
control mice (Ctrl, n= 3 mice), LPS-treated mice (n= 4 mice), or LPS and 
Sivelestat-treated mice (LPS+ Siv, n= 4 mice). p= 0.005 between Ctrl and LPS 
groups (two-tailed t test with Welch’s correction). p= 0.03 between Ctrl and 
LPS +Siv groups (two-tailed t test with Welch’s correction). p= 0.133 between 
LPS and LPS + Siv groups (two-tailed t test).  
(d) Flow cytometry-based quantitation of CD63 median fluorescence intensity 
in CD11b+ Ly6G+ cells in lungs of PBS-treated (Ctrl), LPS-treated mice (n= 4 
mice), or LPS and Sivelestat-treated mice (LPS+ Siv, n= 4 mice). p < 0.0001 
between Ctrl and LPS groups (two-tailed t test). p < 0.0001 between Ctrl and 
LPS +Siv groups (two-tailed t test). p= 0.08 between LPS and LPS + Siv 
groups (two-tailed t test).  
(Data in Figure 3.14 generated in collaboration with Dr. R. Catena. Panel a 
generated by R. Catena.) 
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targeted by Sivelestat to yield significant anti-metastatic phenotypes. 
To confirm that the effect of Sivelestat on metastasis was mediated via Tsp-1, 
we used Tsp-1-/- mice. Notably, Sivelestat was unable to mediate its 
metastasis-suppressive effects in Tsp-1-/- mice (Figure 3.15a). Moreover, in 
the Tsp-1-/- mice, neutrophil recruitment and degranulation remained 
unaffected (Figure 3.15b, c). Taken together, these data further validate 
results obtained from genetic ablation of NE and GG, showing that neutrophil 
protease-mediated degradation of Tsp-1 is necessary for metastasis. 
Furthermore, they provide a potential pharmacological strategy for targeting 
metastasis. 
 
3-3. DISCUSSION 
We have established that lung inflammation induced by external insults 
enhances metastatic progression. We have further deciphered the mechanism 
responsible for this phenotype, and we reveal the novel finding that Ly6G+ 
neutrophils recruited to inflamed lungs degrade Tsp-1 through the action of 
their serine proteases, NE and CG (Figure 3.16).  
 
The metastatic potential of cancer cells has generally been attributed to cell 
intrinsic properties. However, recent studies have brought to light the intricate 
involvement of premetastatic niche components in supporting metastasis (Gao 
et al., 2008, 2012; Kaplan et al., 2005; Kim et al., 2009). While evidence has 
emerged on the interplay between tumor-derived factors and the formation of 
a premetastatic niche with a significant inflammatory component, little is 
known about the role of external inflammation in distant organs on metastasis.  
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Figure 3.15. Sivelestat suppresses metastasis via a Tsp-1-dependent 
mechanism.  
(a) Quantitation of metastatic burden via bioluminescence imaging in PBS-
treated (Ctrl) and Sivelestat-treated (Siv) Tsp-1-/- mice injected with luciferase-
labeled LLC cells. Signals were normalized to the readings obtained at day 4 
for each individual animal. (n= 5 mice per group, p=1.0 at day 18 as 
determined by two-tailed Mann-Whitney U test). Data are represented as 
mean ± SEM.  
(b) Western blot analysis of Tsp-1 protein in lungs of WT PBS-treated (Ctrl) 
lungs (n=2) and Tsp-1-/- lungs treated with PBS (Ctrl) (n=4) or Sivelestat (Siv) 
(n=4). β-actin serves as a loading control.  
(c) Flow cytometry-based quantitation of Ly6G+ cells in Tsp-1-/- lungs treated 
with PBS (Ctrl) or Sivelestat (Siv). (n=4 per group, p= 0.371, as determine by 
two-tailed unpaired t test).  
(d) Flow cytometry-based quantitation of CD63 mean fluorescence intensity 
(MFI) in Ly6G+ cells in lungs of Tsp-1-/- mice treated with PBS (Ctrl) or 
Sivelestat (Siv) (n=4 per group, p= 0.653 as determined by two-tailed unpaired 
t test).  
(Data in Figure 3.15 generated in collaboration with Dr. R. Catena.) 
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Figure 3.16. Proposed model. Under steady state, neutrophil recruitment to 
the lungs is minimal and Tsp-1 protein levels are maintained at a baseline 
necessary for lung homeostasis. Following induction of inflammation either by 
LPS administration or overexpression of IL-1β, myeloid cells are recruited from 
the bone marrow, with Ly6G+ neutrophils being the most abundant. In the lung 
microenvironment, the neutrophils degranulate their azurophilic granules, 
releasing the serine proteases neutrophil elastase (NE) and cathepsin G (CG). 
NE and CG degrade the anti-tumorigenic protein Tsp-1 in the lungs, rendering 
the lung microenvironment more conducive to metastatic outgrowth. 
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Recent work has shown that LPS-induced acute lung inflammation enhances 
breast cancer metastasis to the lung, via a ubiquitin/CXCR4 mechanism (Yan 
et al., 2013), as well as via the upregulation of E-selectin on endothelial cells 
(Jiang et al., 2014). In our study, we have identified a novel mechanism 
governing enhanced metastasis in acutely inflamed lungs. By introducing LPS 
intranasally to induce a lung-restricted inflammatory response, we 
demonstrated that the release of serine proteases NE and CG by the recruited 
BM-derived Ly6G+ neutrophils is necessary for metastasis enhancement. 
These proteases specifically target the potent anti-tumorigenic factor, Tsp-1, 
resulting in its degradation, thereby converting a metastasis-suppressive 
microenvironment to a metastasis-promoting microenvironment. In contrast to 
previous studies, where specific cleavage products of Tsp-1 mediate its 
function, such as the anti-angiogenic fragments generated by thrombin-
mediated and ADAM-TS1-mediated cleavage (Lawler, 1986; Lee et al., 2006b; 
Taraboletti et al., 1997), our findings suggest a novel mechanism of Tsp-1 
regulation in inflamed lungs by the combined proteolytic activity of NE and CG.   
 
Furthermore, this study highlights the functional plasticity of Ly6G+ neutrophils, 
which are both the source of Tsp-1 in the lungs as well as carriers of the 
proteases that degrade it. Under normal physiological conditions, these 
neutrophils appear to produce intact Tsp-1 to maintain an anti-metastatic 
microenvironment. However, under inflammatory conditions, the same 
neutrophils degranulate NE and CG from their azurophilic granules, degrading 
Tsp-1, and generating a metastasis-promoting microenvironment. Neutrophil 
plasticity has also been described in other studies. For example, tumor-
derived TGFβ converts neutrophils from a cytotoxic into a protumorigenic “N2” 
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phenotype (Fridlender et al., 2009). In contrast, tumor-entrained neutrophils 
(TENs) are recruited to premetastatic lungs, where they function to block 
metastatic seeding (Granot et al., 2011). In our study, neutrophils are not 
reprogrammed by tumor cells, but rather respond to inflammatory stimuli, and 
Tsp-1 degradation is a consequence of this response, rendering the 
microenvironment more metastasis-conducive.  
 
We have shown that Tsp-1 degradation is not unique to the LPS model of 
inflammation, as a similar inflammatory phenotype pertaining to neutrophil 
recruitment and degranulation, and cytokine production is recapitulated in a 
genetic model of lung inflammation, where IL-1β is ectopically expressed by 
lung epithelial cells. Notably, in this model, we also observed increased NE 
and CG activity and Tsp-1 degradation. These results suggest that the 
mechanism governing the metastasis-enhancing effect of inflammation is a 
more generalizable phenomenon, and is not only limited to LPS-mediated 
inflammation.  
 
We demonstrated that LPS-mediated lung inflammation promoted metastasis 
of orthotopic primary tumors.  However, to determine the molecular 
mechanisms by which neutrophil-mediated lung inflammation contributes to 
metastatic outgrowth, we resorted to an experimental metastasis model since 
the orthotopic primary tumors systemically generate BM-derived premetastatic 
niches with inflammatory characteristics in distal target organ (Hiratsuka et al., 
2013). Consistent with this notion, the lungs of tumor-bearing control (- LPS) 
mice showed increased recruitment of BM-derived CD45+ cells compared to 
non-tumor bearing mice (Figure 3.3c), suggesting that an experimental 
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metastasis model would allow us to study the effect of lung-specific external 
inflammation on the outgrowth of tumor cells, thus circumventing the 
confounding effects of primary tumor-generated inflammatory premetastatic 
niches. 
We generated inflammation prior to tumor cell inoculation, hence preparing the 
microenvironment, or “soil,” for the arriving tumor cells, or “seed”. Using the 
orthotopic model of inflammation presented more challenges, since the timing 
of acute inflammation is critical to the metastatic outcome. We suspect that 
disseminating tumor cells that encounter the acutely inflamed lung 
microenvironment, with actively degranulating neutrophils, will be lysed, 
negatively impacting metastatic outcome. With that limitation in mind, it is not 
surprising that our early experiments with orthotopic tumor metastasis yielded 
highly variable results, since we cannot tightly control the timing of tumor cell 
dissemination from the primary site. This was the major reason for using the 
tail vein model to probe the mechanisms involved in inflammation-driven 
metastasis.   
 
Of significant interest was the observation that metastasis was suppressed in 
mice that were deficient for NE and CG, or mice that were treated with the 
dual protease inhibitor Sivelestat. Furthermore, this metastasis-suppressive 
phenotype was abolished in Tsp-1-/- mice. As expected, Sivelestat, inhibited 
NE (Hagio et al., 2004, 2005); however, strikingly, we found that Sivelestat 
also inhibited CG, thereby exhibiting dual protease inhibitor activity. This dual 
activity can be explained by the observation that the chymotrypsin-like serine 
proteases CG and NE exhibit homology in primary amino acid sequence (37% 
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identical), homology in their tertiary structures, and the residues of the catalytic 
triad are at identical positions (His57, Asp102 and Ser195) (Averhoff et al., 2008).   
 
Importantly, having observed a metastasis-inhibitory phenotype with Sivelestat 
treatment, and since it is currently in phase III clinical trials for the treatment of 
ALI associated with SIRS (Aikawa and Kawasaki, 2014; Aikawa et al., 2011; 
Iwata et al., 2010), we propose repurposing it for the treatment or prevention 
of metastatic progression. This will be discussed in greater detail in Chapter 
Four. 
 
While we agree with the current notion that therapy should be targeted not 
only against tumor cells, but also against the host microenvironment, our 
studies suggest that targeting neutrophils may not be a viable strategy in light 
of their dual role as metastasis-suppressive and metastasis-promoting. 
Targeting neutrophils may neutralize their anti-metastatic effects derived from 
Tsp-1 production, which is why we believe that targeting the NE/CG- Tsp-1 
axis may have clinical value in the prevention of metastasis or inhibition of its 
outgrowth. 
 
3-4. MATERIALS AND METHODS 
3-4.1. Mice and cell lines  
All animal work was conducted in accordance with a protocol approved by the 
Institutional Animal Care and Use Committee. Wild type C57BL/6J, NE 
knockout B6.129X1-Elanetm1Sds/J, and Tsp-1 knockout B6.129S2-Thbs1tm1Hyn/J 
mice were obtained from The Jackson Laboratory (Bar Harbor, Maine). CG 
knockout Ctsgtm1Ley mice in C57BL/6J strain were a gift from Dr. Christine 
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Pham, (Washington University, St. Louis, MO). NE, CG, and Tsp-1 knockout 
mice in the C57BL/6J background were bred and genotyped according to 
standard protocols. 8-week-old female mice of the above-mentioned 
genotypes were used for experiments.  
CCSP-rtTA and tetO-IL-1β mice in the FBV/N background (gift from Dr. Jeffrey 
Whitsett, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH) were 
bred to yield the bitransgenic CCSP-rtTA; tetO-IL-1β mice. 8-week-old male 
and female bitransgenic mice were used for experiments. 
Murine LLC cell stably expressing RFP and firefly luciferase, were cultured in 
DMEM supplemented with 10% fetal bovine serum (Catena et al., 2013; Gao 
et al., 2008).  
Murine B16-BL6 melanoma cells (gift from Dr. Randolph Watnick at Boston’s 
Children Hospital, MA) were cultured in DMEM supplemented with 10% fetal 
bovine serum (Nakamura et al., 2002). 
 
3-4.2. Bone marrow isolation and transplantation 
BM harvest and transplantation was performed using our published methods. 
BM transplantation was performed by injecting 1x107 total BM cells via the 
retro-orbital sinus of lethally irradiated (900 rads) 8-week old C57BL/6 female 
mice. BM cells were harvested by flushing femurs and tibias of donor animals 
including Wild-type, Tsp-1-/-, NE-/-, CG-/-, and NE-/-CG-/- mice in 1X PBS. After 4 
weeks of BM engraftment, reconstitution efficiency was monitored by PCR of 
genomic DNA from peripheral blood for absence of Tsp-1, NE, and CG.  
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3-4.3. Metastasis assay, bioluminescence imaging, and analysis  
For experimental metastasis, 8-week old C57BL/6 mice were injected via tail 
vein with 5 x 105 luciferase-labelled LLC cells, or 2 x 105 B16-BL6 unlabeled 
melanoma cells in a volume of 100 µl PBS. LLC pulmonary metastases were 
monitored by live animal bioluminescence imaging (Xenogen) once per week. 
Briefly, mice were anaesthetized and injected in the retro-orbital sinus with 75 
mg/kg of D-luciferin in 50 µL.  For BLI plots, photon flux was calculated for 
each mouse by using the same circular region of interest encompassing the 
thorax of the mouse.  
B16-BL6 pulmonary metastases were assessed by stereology following H&E 
staining of the lungs, 18 days after tumor cell intravenous injection. 
 
To study metastasis from orthotopic tumors, 8-week old C57BL/6 mice were 
injected subcutaneously in the flank with 105 B16-BL6 unlabeled melanoma 
cells in a total volume of 50 µl PBS. After 3 weeks of primary tumor growth, 
LPS was administered intranasally on days 0, 3, and 7. Primary tumors were 
then resected on day 10, and a few lungs were harvested for analysis of 
neutrophil recruitment. Metastasis was allowed to progress for 3 more weeks, 
at which time all lungs were harvested for H&E staining and stereology. 
 
3-4.4. LPS treatments 
LPS derived from E. coli strain 0111:B4 was purchased from Sigma Chemical 
Co., (St. Louis, MO, USA). Mice were anaesthetized using isofluorane, and 
LPS was administered intranasally in a 50 µl volume at a concentration of 0.25 
mg/ml, for a dose of 12.5 µg (Matute-Bello et al., 2004; Yan et al., 2013) on 
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days 0, 3, and 7. In the case of tumor-free experiments, lungs were collected 
at day 10 (3 days after the last LPS treatment) and analyzed. 
In experiments assessing metastatic growth of tail vein-injected cells following 
LPS treatment, 5 x 105 LLC cells or 2 x 105 B16-BL6 melanoma cells were 
injected intravenously via the tail vein three days after the end of LPS 
treatment.  
 
3-4.5. Sivelestat treatments 
In vivo, 5 mg/kg Sivelestat dissolved in 1X PBS (ONO-5046, TOCRIS 
Bioscience, Bristol, UK) was administered daily via the intraperitoneal route in 
a volume of 100 µl. Sivelestat injections started 5 days after the intravenous 
injection of LLCs and were carried on until the termination of the experiment.  
 
3-4.6. In vitro Tsp-1 proteolysis assays 
Recombinant Tsp-1 (R&D systems, 200 ng) was incubated with recombinant 
Cathepsin G (Genway, 100 ng) or recombinant neutrophil elastase (R&D 
systems, 50 ng), in the presence of the neutrophil elastase inhibitor N-
(Methoxysuccinyl)-Ala-Ala-Pro-Val-chloromethyl ketone (Sigma, 50 nmol), the 
cathepsin G inhibitor Z-Gly-Leu-Phe-CMK (MP Biomedicals, France, 50 nmol), 
or Sivelestat (TOCRIS, 1 µg). 
NE or CG enzymes were pre-incubated with inhibitors for 15-30 min at room 
temperature. Then Tsp-1 was incubated with the enzymes or the enzyme-
inhibitor reactions for 15 min at 37°C. 
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3-4.7. Neutrophil isolation, culture, and degranulation 
Bone marrow cells were harvested from femurs and tibias of wild type 
C57/BL6 mice or NE-/-CG-/- mice by flushing the bones with 1X PBS. Total 
bone marrow cells were then subjected to magnetic bead isolation using the 
anti-Ly6G microbead kit (MACS Miltenyi Biotec). Ly6G+ cell population purity 
was then assessed by flow cytometric analysis.  
Approximately 3 million cells were seeded in a total volume of 200 µl of serum-
free RPMI in wells of a 48-well plate. Cells were cultured for 30 min at 37°C in 
DMSO vehicle (final concentration 0.01% DMSO), or 20nM TPA (12-O-
tetradecanoylphorbol-13-acetate, Cell Signaling Technology, MA). Neutrophil 
cell conditioned medium was collected by centrifuging the cells (300xg for 10 
min at room temperature). Degranulation of cells was measured by flow 
cytometric analysis using the marker CD63. The conditioned medium was 
incubated at 37°C for the indicated time points, with or without the addition of 
Sivelestat (final concentration of 0.05 μg/μl), followed by analysis for proteases 
activity and Tsp-1 protein levels.  
 
3-4.8. NE and CG activity assays  
After in vitro degranulation of Ly6G+ cells, protease activity was measured in 
conditioned media. NE activity was measured using EnzChek Elastase assay 
kit (Molecular Probes, Oregon), and CG activity was measured using 
Sensolyte 520 Cathepsin G assay kit (AnaSpec, CA) according to the 
manufacturer’s protocols. 
For protease activity analysis from lung samples, lung protein was extracted in 
1X RIPA buffer without protease inhibitors. For NE activity, analysis was 
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conducted with 40 µg of protein. For CG activity, analysis was conducted with 
5 µg of protein. 
 
3-4.9. Microscopy  
Animals were euthanized at the end of experiments and lungs were quickly 
perfused by injecting 5 mL of 1X PBS through the right ventricle of the heart.  
One part of the lung from each animal was fixed in 3.7% formaldehyde 
overnight and the other part was collagenase-A treated to create a 
homogeneous cellular solution and analyzed by flow cytometry or snap-frozen 
for RNA or protein extraction. 
For microscopy, following formaldehyde fixation, tissues were cryo-embedded 
in Tissue-Tek O.C.T. embedding compound (Electron Microscopy Sciences).  
Lungs were sectioned at a 7 μm thickness. Lung sections were stained with 
hematoxylin and eosin for morphometric determinations. 
Immunohistochemistry for myeloperoxidase was performed using the Pierce 
myeloperoxidase polyclonal rabbit antibody solution (Thermo Scientific, IL), 
and the EnVision+ System HRP-labelled anti-rabbit (DAB+) (Dako). 
 
3-4.10. Tissue sampling and Stereology 
Lungs were perfused by injecting 5 mL of cold PBS through the right ventricle 
of the heart. Lungs were then fixed in 3.7% formaldehyde overnight, followed 
by 2 days in 30% sucrose at 4°C. To prevent tissue shrinkage that occurs 
during paraffin embedding, lungs were cryo-embedded in Tissue-Tek O.C.T. 
embedding compound (Electron Microscopy Sciences), snap frozen on dry 
ice, and stored at -80°C until further sampling. 
124 
 
For systematic uniform and random sampling (SURS) (Nielsen et al., 2001), 
the frozen lungs were sectioned along the coronal plane, with the first cut 
starting at a random position, and the entire lung cut into 1.0 mm-thick parallel 
slabs, resulting in six to seven slabs per lung. Cryostat sections from each 
slab were 7μm thick. Sections were stained with hematoxylin and eosin. 
The stereological measurements of lung and metastasis volumes were 
performed using the Axiovision 4.8 software (Carl Zeiss Inc.) area 
measurement function and following the Cavalieri principle: 
V = T * Σ Areas 
where T is the slab thickness, or intersectional distance (1.0 mm as indicated 
above), and Areas are measured from one section per slab, and added up for 
the entire 6-7 slabs. 
Finally, data was presented as percent metastasis volume per lung volume. 
 
3-4.11. Flow cytometry and cell sorting 
To obtain single cell suspensions, lungs were minced and then digested in 
collagenase/DNase mix (Roche) for 30 min at 37ºC. Cells were washed, 
strained and resuspended in FACS staining buffer (PBS + 2mM EDTA, 1% 
BSA). For analysis of peripheral blood, blood was collected from the tails of 
mice in anti-coagulant buffer (PBS with 5 mM EDTA). Red blood cells were 
eliminated by incubation in RBC Lysis Buffer (5 Prime) for 10 min on ice. Cell 
suspensions were pre-blocked in FACS buffer  plus Fc block (CD16/CD32, 
1:100, BD Biosciences Pharmingen) and then incubated with the following 
primary antibodies:  rat IgG2ακ and IgG2αβ isotype control (BD Pharmingen), 
Ly6G (Clone 1A8, BD Pharmingen), Ly6C (Clone HK1.4), Gr1 (Clone RB6-
8C5, Biolegend), CD11b (clone M1/70, BD Pharmingen), CD45 (Clone 30-F1, 
125 
 
Biolegend), CD3 (Clone 17A2, Biolegend), B220 (Clone RA3-6B2, Biolegend), 
CD25 (Clone PC61, Biolegend), CD49b (Clone DX5, BD Pharmingen), cKit 
(Clone 2B8, BD Pharmingen), VEGFR1 (BD Pharmingen), CD11c (Clone 
N418, Biolegend), and CD63 (Clone NVG-2, Biolegend). SYTOX blue 
(Invitrogen) was added and incubated for 5 minutes at room temperature in 
each cell staining tube to facilitate the elimination of dead cells during flow 
cytometry.   
Labelled cell populations were measured by LSRII flow cytometer coupled with 
FACSDiva software (BD Bioscience). Flow cytometry analysis was performed 
using a variety of controls including isotype antibodies, single color controls, 
and unstained samples for determining appropriate gates, voltages, and 
compensations required in multivariate flow cytometry. For sorting, targeted 
cell populations were gated within FACSDiva software and sorted by Aria II 
sorter (BD Bioscience). For sorting, SYTOX blue-negative gate was utilized to 
remove dead cells. CD11b+ Ly6G+ subset was isolated and processed for 
RNA isolation using PicoPure RNA isolation kit (Arcturus). 
 
3-4.12. Quantitative RT-PCR analysis  
Total RNA from flow cytometry sorted cells was extracted using the PicoPure 
RNA extraction kit (Arcturus) following the manufacturer´s protocol.  RNA was 
converted to cDNA using qScript™ cDNA supermix (Quanta Biosciences). Q-
PCR was performed with primers and iQTM SYBER Green master mix 
(Biorad, Hercule, CA). Each sample was duplicated to minimize pipetting error. 
A standard protocol of initial denaturing at 95°C for 10 min, 40 cycles of 95°C 
for 10 sec, 60°C for 30 sec, and 72°C for 30 sec, followed by final extension at 
72°C for 5 min and melt curve analysis was applied on a BioRad CFX96 Real 
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Time System (BioRad) coupled with Bio-Rad-CFX Manager software. The 
relative abundance of each transcript compared with the control was 
calculated utilizing the delta-Ct method.  
The primer sequences used for RT-PCR were:  
Mus-GAPDH-for: CATGGCCTTCCGTGTTCCTA 
Mus-GAPDH-rev: GCGGCACGTCAGATCCA 
Mus-Tsp-1-for: CTTGAGGCAGATGAAGAAGACC 
Mus-Tsp-1-rev: ACTGACACCACTTGTTGCTTCC 
Mus-IL-6-for: AGACAAAGCCAGAGTCCTTCAG 
Mus-IL-6-rev: TTAGGAGAGCATTGGAAATTGG 
Mus-IL-1β-for: TGTGTAATGAAAGACGGCACAC 
Mus-IL-1β-rev: TCAAACTCCACTTTGCTCTTGA 
Mus-TNFα-for: GTCTACTGAACTTCGGGGTGAT 
Mus-TNFα-rev: TTGAGAAGATGATCTGAGTGTGAG 
Mus- Cox-2-for: CCATTGACCAGAGCAGAGAGAT 
Mus- Cox-2-rev: CTTTCAATTCTGCAGCCATTTC 
  
3-4.13. Western blot analysis  
Cells were homogenized in lysis buffer (BioRad) containing protease inhibitors 
(Roche Applied Science). Samples were boiled for 5 min in 1x SDS sampling 
buffer plus 10% β-mercaptoethanol, and loaded onto 4-12% gradient Bis-Tris 
NuPAGE gels (Invitrogen). Western blotting was performed using antibodies 
specific for Tsp-1 (Clone Ab-11, Labvision) and β-actin (Sigma-Aldrich).  
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3-4.14. Statistical analysis  
Results were expressed as mean ± SEM depicted by error bars, unless 
otherwise stated. Analyses of different treatment groups were performed using 
the Mann-Whitney U or Student t tests, using the GraphPad Prism statistics 
software. p values < 0.05 were considered significant. 
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CHAPTER FOUR 
FUTURE DIRECTIONS AND CLINICAL IMPLICATIONS 
 
4-1. FUTURE DIRECTIONS 
 
In Chapter Two, we have demonstrated that metastasis-incompetent tumor 
cells, by virtue of secreting prosaposin, can induce the expression of Tsp-1 in 
myeloid cells recruited to the metastatic organ, rendering the lungs refractory 
to tumor outgrowth. We have further shown that the psap-derived DWLPK 
peptide, which retains the Tsp-1-inducing activity, can be used to suppress 
metastasis by upregulating Tsp-1 production in lung myeloid cells. In future 
studies, it would be of interest to determine the receptor responsible for 
relaying the psap/DWLPK signal leading to Tsp-1 induction in myeloid cells. 
Our preliminary investigations suggest that LRP1 is the receptor on myeloid 
cells involved in this signaling event. We plan to elucidate the signaling 
cascade downstream of LRP1 that leads to Tsp-1 expression. Biochemical 
and mutational analysis will allow us to determine the domains on LRP1 that 
are required for binding and responding to Psap or DWLPK. This will be 
carried out by expressing mutants of LRP1, each containing different clusters 
of ligand-binding repeats of the extracellular domain, in LRP1-deficient cells 
(293Ts) in the presence and absence of DWLPK. This approach was utilized 
to determine the α2-macroglobulin-binding domains of LRP1 (Mikhailenko et 
al., 2001). Based on the induction of Tsp-1 in response to culture with 
DWLPK, we will be able to deduce the LRP1 domains necessary and sufficient 
for relaying psap/DWLPK signals.  
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Furthermore, we will identify the intracellular signaling cascades that become 
activated downstream of DWLPK- ligated LRP1, leading to Tsp-1 expression. 
Two potential players that have been reported to be activated downstream of 
LRP1 are the RhoA and Rac1 GTPases (Mantuano et al., 2010). Hence, we 
will inhibit members of these pathways by using existing pharmacological 
inhibitors, and determine the subsequent response of the cells to DWLPK. For 
instance, RhoA activates the downstream effector Rho kinase (ROCK), which 
will allow us to use the Rho Kinase inhibitor, Y27632, to block that signaling 
cascade. We will also use the Rac1 inhibitor, NSC23766, to inhibit Rac1-
mediated signaling. The absence of Tsp-1 induction would implicate the 
pathway or signaling component in the response of cells to DWLPK. 
 
The findings from these experiments will allow us to address whether LRP1 on 
myeloid cells is required for the suppression of metastasis observed in 
response to DWLPK. Myeloid-specific LRP1 knockout mice (LRP1f/f LysM-
Cre+/+) will be treated with DWLPK and administered luciferase-labeled LLC 
cells via the tail vein. Metastasis will be compared to WT mice treated with 
DWLPK. If myeloid cell LRP1 is required for DWLPK-mediated metastasis 
suppression, then we expect LRP1f/f LysM-Cre+/+ mice treated with DWLPK 
not to exhibit metastasis suppression, compared to WT mice. These 
transgenic mice will provide the most compelling assessment of the role of 
LRP1 specifically in myeloid cells, as these cells are the main producers of 
Tsp-1. This genetic approach provides superior specificity compared to the 
pharmacological inhibitor of LRP1, RAP, which will systemically block LRP1 
function in vivo in all cells that express the receptor. 
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In Chapter Three, we uncovered a unique mechanism whereby neutrophils 
recruited to inflamed lungs degrade Tsp-1 through the action of their serine 
proteases, NE and CG. Notably, this mechanism enhanced metastatic 
outgrowth, as protease deficient NE-/- CG-/- mice intravenously challenged with 
LLC cells showed significant metastasis suppression, compared to their WT 
counterparts. It would be important to determine whether the proteases-
mediated degradation of Tsp-1 is the only mechanism for the ensuing 
metastatic phenotype, as these proteases could also enhance metastasis by 
remodeling the ECM (Helske et al., 2006; Kafienah et al., 1998; Sköld et al., 
1999; Zhu et al., 2001). To address this, we can generate NE-/- CG-/- Tsp-1-/- 
mice, challenge them with LPS, and monitor the metastatic outgrowth of LLC 
or B16-BL6 melanoma. If indeed Tsp-1 degradation is the major mechanism 
by which NE and CG enhance metastasis, then metastasis suppression 
observed in NE-/- CG-/- mice will be lost in NE-/- CG-/- Tsp-1-/- mice. On the 
other hand, if another NE and CG-mediated mechanism is also at play, then 
we would observe partial metastasis suppression in NE-/- CG-/- Tsp-1-/- mice, 
compared to WT mice, with NE-/- CG-/- mice showing the most efficient 
suppression. 
 
Our Sivelestat metastasis suppression studies (Figure 3.13, 3.14) were 
conducted in the absence of LPS challenge, and need to be repeated in the 
presence of LPS-driven lung inflammation. However, this does not undermine 
the mechanistic results obtained with NE-/- CG-/- mice, where metastasis is 
suppressed in LPS-inflamed lungs in the absence of the two proteases. 
 
 
131 
 
4-2. CLINICAL IMPLICATIONS 
 
Our findings suggest that therapeutic interventions that upregulate Tsp-1 
levels or block its degradation could have an anti-metastatic potential. 
 
4-2.1. Novel therapeutics to induce Tsp-1 in lung myeloid cells 
Our finding that tumor-derived psap has a metastasis-inhibitory function, and 
our demonstration that DWLPK peptide suppresses metastasis in vivo offers 
the opportunity to develop the peptide into a therapeutic agent for the 
treatment or prevention of metastasis. As a therapeutic agent, the peptide 
provides certain advantages, as peptides are highly specific for their molecular 
targets, reducing the potential for undesirable off-target side-effects, which is a 
common shortcoming of non-peptide small molecule drugs (Craik et al., 2013). 
For that purpose, a more stable and bioavailable version of the peptide will 
have to be synthesized to increase the therapeutic benefit in vivo. The peptide 
we used in our experiments was chemically altered to include an N-terminal 
acetyl group and a C-terminal amide group, protecting it from serum and 
tissue proteases (McGregor, 2008). We will also test a cyclized version of the 
peptide, since cyclization is shown to further stabilize peptides against 
proteases (Werle and Bernkop-Schnürch, 2006). Another important factor 
consider to make DWLPK a viable therapeutic is increasing its bioavailability. 
Being a small peptide, DWLPK faces rapid clearance from the circulation by 
the kidneys. One way to improve its half-life in circulation is to attach 
polyethylene glycol (PEG) molecules to increase its molecular weight and 
retard its excretion (McGregor, 2008; Werle and Bernkop-Schnürch, 2006). 
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Another clinically relevant application of our findings is the potential activation 
of LRP1 signaling to induce Tsp-1 and suppress metastasis. We propose that, 
aside from DWLPK, we could develop an antibody that binds to the same 
region of LRP1 and hence mimics the effect of the peptide. This could be 
beneficial since the antibody would bind with even greater affinity to its antigen 
on LRP1 than the DWLPK peptide, improving the biological effect. 
Furthermore, antibody therapeutics are known to possess improved 
pharmacokinetic properties compared to small peptides, with serum half-lives 
on the order of days, compared to hours for peptides (Craik et al., 2013; Imai 
and Takaoka, 2006). This is because high molecular weight antibodies are 
rarely filtered by kidneys, and are rather reabsorbed or subjected to 
catabolism (Lobo et al., 2004). Moreover, based on the finding that IgG has a 
significantly longer serum half-life than other immunoglobulin isotypes due to 
its binding to the receptor FcRn (Fc receptor of the neonate), protecting it from 
catabolism in the lysosome, we can foreseeably develop an antibody carrying 
the Fc portion of IgG to extend its half-life (Beck et al., 2010; Lobo et al., 
2004). Furthermore, generating a chimeric or humanized antibody will help 
reduce its immunogenicity and clearance when used in humans (Beck et al., 
2010; Lobo et al., 2004). 
 
4-2.2. Tsp-1 mimetic peptide ABT-510 
A Tsp-1 mimetic peptide, ABT-510, has been developed that reproduces Tsp-
1 anti-angiogenic activity. ABT-510 is a modified nonapeptide, derived from 
the anti-angiogenic properdin type 1 repeats of Tsp-1 (Baker et al., 2008). It 
competes with Tsp-1 for binding to endothelial cells and inhibits VEGF- and 
bFGF-stimulated endothelial cell migration (Baker et al., 2008). Moreover, 
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ABT-510 was found to inhibit angiogenesis in vivo and significantly suppress 
LLC tumor growth in lungs (Haviv et al., 2005). ABT-510 is currently in clinical 
trials for the treatment of several solid tumors. Despite its favorable toxicity 
profile, phase II trials for soft tissue sarcoma, metastatic melanoma, and 
advanced renal cell carcinoma have not yielded satisfying results for use of 
ABT-510 as a monotherapy (Baker et al., 2008; Ebbinghaus et al., 2007; 
Markovic et al., 2007). However, mouse experimental models using ABT-510 
as an adjuvant chemotherapy have yielded more promising outcomes, as in 
the case of ovarian cancer, where ABT-510 boosts the antitumor effect of 
cytotoxic chemotherapy (Campbell et al., 2010; Greenaway et al., 2009).  
Based on our results with DWLPK suppressing metastasis, we believe that 
DWLPK will be a more successful anti-metastatic therapeutic agent than ABT-
510 because it induces the endogenous expression of full-length Tsp-1 by 
myeloid cells. 
 
4-2.3. Inhibiting NE and CG proteases using Sivelestat 
The metastasis-suppressive phenotype observed with Sivelestat suggests that 
it could be used as a therapeutic to block metastatic progression, even in the 
absence of external inflammation. This is based on our preliminary data 
showing that inflammation derived from a primary tumor exhibits a similar 
phenotype of Tsp-1 degradation as LPS-driven inflammation. Moreover, since 
Tsp-1-deficient mice didn’t benefit from the effect of Sivelestat on metastases, 
it logically follows that Sivelestat mediates metastasis suppression via a 
mechanism that requires Tsp-1. Our data suggest that Sivelestat inhibits NE 
and CG activity, blocking Tsp-1 proteolysis, hence suppressing metastasis. 
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Sivelestat has been described and marketed as a specific NE inhibitor, and 
used for the treatment of ALI in Japan and the Republic of Korea, with phase 
III and a postmarketing phase IV trial finding that it enhances overall patient 
outcome and shows no increase in adverse events compared to placebo 
treatment (Aikawa and Kawasaki, 2014; Aikawa et al., 2011; Iwata et al., 2010; 
Zeiher et al., 2004). The pathogenesis of ALI involves lung accumulation of 
neutrophils, which release reactive oxygen species and several proteases, 
among which NE plays an important role in the etiology of ALI (Kodama et al., 
2007; Zeiher et al., 2002). In that regard, Sivelestat treatment was observed to 
repress neutrophil recruitment and downregulate NE activity (Kawabata et al., 
2000). For our purposes, having determined that Sivelestat is a dual inhibitor 
of NE and CG, and observing metastasis suppression in NE-/- CG-/- BMT mice, 
we suggest repurposing Sivelestat for the treatment or prevention of 
metastatic progression. 
The serum half-life and bioavailability of Sivelestat are major limiting factors to 
its activity in vivo. For this reason, in the human trials for the treatment of ALI, 
Sivelestat is continuously administered intravenously at a rate of 0.2 
mg/kg/hour for a maximum of 14 days (Aikawa and Kawasaki, 2014; Aikawa et 
al., 2011; Miyoshi et al., 2013). This justifies using osmotic pumps in our 
mouse experiments to determine more accurately the effect of Sivelestat on 
inflammation-enhanced metastasis. In our studies, a short serum half-life 
could be a hindrance to targeting protease activity and suppressing 
metastasis, especially in the context of inflammation, where neutrophils are 
constantly being recruited and releasing active proteases. Hence, by 
administering Sivelestat via osmotic pumps, we could determine if a 
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continuous low dose of Sivelestat could more steadily block protease activity 
and prove to be a more efficient way of suppressing metastasis. In a model of 
ALI in mice exposed to aerosolized LPS, intravenous infusion of Sivelestat 
showed reversal of the ALI phenotype, inhibiting NE activity and suppressing 
the recruitment of neutrophils (Kawabata et al., 2000). Similarly, intravenous 
Sivelestat infusion has been used as a delivery route in a model of acute 
pancreatitis in rats (Cao and Liu, 2013) and LPS-driven intestinal paralysis and 
hypotension in hamsters (Hara et al., 2008). 
 
Given that Sivelestat can protect Tsp-1 from cleavage by neutrophil proteases, 
it is plausible that Sivelestat could be blocking the progression of already 
existing micrometastases in the lungs, either by blocking the angiogenic switch 
or by suppressing tumor cell proliferation. In this respect, keeping the nodules 
in a micrometastatic state could make them easier to target by chemotherapy, 
radiotherapy, or surgical resection. Hence, Sivelestat could foreseeably be 
used in combination with standard of care chemotherapy, radiotherapy, or in 
the neoadjuvant setting before surgical resection. 
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